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Macrophages play a major role in the innate immune response to infection. CD4+ T cels 
and macrophages are the target cels for HIV, the virus that causes AIDS, and cause 
establishment of infection in the brain. HIV infection of the brain often leads to chronic 
inflammation and HIV-associated neurocognitive disorders (HAND). Our lab has 
developed an SIV macaque model of HIV to study CNS disease and the role of 
macrophages and other cel types involved in these disorders.  
 
Host celular restriction factors inhibit HIV replication, and miRNAs are a member of 
this group. These smal RNA molecules fine-tune gene expression through targeting 3’ 
UTRs of mRNAs and inhibiting translation and/or causing mRNA degradation. 
Recently, there has been increased interest in miRNA regulation of viruses due to their 
role in pathogenesis of HIV-1 and other viruses.  
 
In our studies, microaray analysis demonstrated levels of specific miRNAs that differ 
between monocytes (HIV-restricted) and macrophages (HIV-permissive) immune cels. 
These results suggest miRNAs may restrict virus infection, and also limit infection within 
target cel populations. Several miRNAs affect IFNβ, a cytokine induced early after HIV 
infection. Many genes are activated by IFNβ, and its regulation is critical for controling 
immune signaling. miRNAs, miR-26a, -34a, -145 and –let7b have predicted binding sites 
in the IFNβ 3’ UTR. An ELISA showed each of these miRNAs regulates IFNβ protein 
levels and RT-qPCR data demonstrates that mature miRNAs miR-26a, -34a and –let7b 
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were induced by IFNβ, indicating that IFNβ signaling induces miRNAs that then regulate 
expression of the protein.  
 
We also identified miRNAs that target SIV RNAs and inhibit virus replication. The SIV 
3’ UTR contains functional binding sites for four different miRNAs, miR-29a, -29b, -9 
and -146a, determined by RNA immunoprecipitation. Using primary macrophages, we 
found each miRNA reduced intracelular viral RNAs, as wel as production of virus in 
supernatants of infected cels. RT-qPCR assays indicated modulation of mature miRNAs 
and primary miRNA transcripts by IFNβ and TNFα. These results demonstrate 
transcriptional regulation of miR-29a, -29b, -9 and -146a, four miRNAs that regulate 
virus replication in cels essential for immune signaling. 
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 microRNAs (miRNAs) are ~22-nucleotide non-coding RNA molecules found in 
plants and animals that fine-tune expression of proteins within a cel. miRNAs regulate 
protein expression canonicaly through binding to the ends (3’ untranslated 
regions/UTRs) of target mRNAs and decrease protein production by either mRNA 
degradation or translation suppression [1]. miRNAs were reported in 1993 in describing 
gene regulation in a developmental study of Caenorhabditis elegans (C. elegans) [2], a 
model organism used commonly used for genetic analyses. The majority of these smal 
RNAs are initialy transcribed by RNA Polymerase II which produces long primary 
miRNAs (pri-miRNAs) [3]. The mature miRNA sequence within the pri-miRNA forms a 
hairpin structure and while in the nucleus, the Drosha-DGCR8 protein complex [4] 
recognizes the hairpin. Drosha, with its RNase III activity, cleaves the pri-miRNA into an 
~80-nucleotide precursor miRNA (pre-miRNA), removing the hairpin from the nascent 
transcript. The pre-miRNA is then transported from the nucleus to the cytoplasm by 
Exportin 5 [5], a nucleocytoplasmic transport protein. In the cytoplasm, the pre-miRNA 
hairpin is further processed by Dicer [6], another enzyme with RNase III activity, which 
removes the loop joining the two arms of the pre-miRNA duplex. One strand of the 
duplex is loaded into the RNA-induced Silencing Complex (RISC). RISC is a complex of 
several proteins that uses the miRNA strand to locate and bind to mRNA target(s). The 
first 2-8 nucleotides at the 5’ end of the miRNA contains the seed region. The overal 
complementarity of the seed region with the seed-binding region in a target mRNA 
sequence is the most important factor in determining binding specificity [7]. There are 
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estimated to be over 1000 human microRNAs [8] predicted to target approximately 60% 
of the genome [9, 10]. miRNAs are present in al human cel types and are involved in 
processes ranging from organism development [11, 12] to antiviral defenses [13-17] and 
viral pathogenesis [18-21]. 
 
microRNAs related to viral infection and pathogenesis 
 miRNAs have been shown to regulate infection by many viruses including 
influenza, herpes viruses, Hepatitis C (HCV) and HIV-1, by reducing the replication of 
the virus and limiting the spread of infection to uninfected cels. miRNAs miR-323, -491 
and -654 inhibit replication of H1N1 influenza A viruses through binding to a conserved 
region of the PB1 gene [20]. The protein encoded by this gene is an essential subunit of 
the viral RNA Polymerase I that is required for transcription of the viral genome. In 
addition, infection of human lung cel lines with H1N1 influenza A virus affects 
expression levels of many miRNAs [22], and mice infected with different strains of 
influenza A also show changes in miRNA expression [23]. A Kaposi’s sarcoma-
associated herpesvirus (KSHV), and Epstein-Bar virus (EBV), contain genes regulated 
by miR-1293 [24] and miRNAs in the miR-17 family [25], respectively. HCV presented 
an interesting case where miR-122 binds the 5’ UTR of HCV and increases virus 
replication [18]. An antagonist of this miRNA has been through clinical trials and wil be 
available to treat HCV early in 2014. HIV-infected individuals show changes in miRNA 
profiles compared to uninfected individuals [26, 27] and specific miRNAs have been 
shown to target HIV-1 mRNA sequences and reduce virus production [19, 28-31]. 
 
 4 
History of HIV-1 
 Human Immunodeficiency Virus (HIV) is the virus that causes Acquired 
Immunodeficiency Syndrome (AIDS). Simian Immunodeficiency Virus (SIVcpz) is a 
closely related lentivirus that infects chimpanzees in Africa. Phylogenetic studies of 
SIVcpz and HIV-1 strains suggest there have been four cross-over events of SIV into 
humans [32] most likely caused by hunting of infected non-human primates [33]. 
Because of the genetic relationship established between HIV-1 and SIV, it is now 
understood that al human HIV-1 infections were acquired from one particular 
chimpanzee subspecies and that chimpanzees are the natural reservoir for SIVcpz, the 
virus from which HIV-1 originated [32, 34]. 
 Based on genetic evaluation of different virus strains, HIV-1 is estimated to have 
appeared in humans in the 1920s [34] and HIV/AIDS was first recognized in patients in 
the United States in 1981. The World Health Organization 2011 report shows there are 
approximately 34 milion people currently infected with HIV. The region of the world 
most impacted by HIV has been sub-Saharan Africa, but this disease became, and 
continues to be, a global pandemic. Since the peak of the pandemic in 1997, the total 
global number of new HIV infections has been declining [35]. A decline in new 
infections beginning in 2005-2006 has continued along with decreasing AIDS-related 
deaths. While these numbers are declining, there were stil 2.5 milion new infections in 
2012 and over 1.5 milion deaths [35], demonstrating the continuing impact of this virus 
on the world population. The decline in AIDS-related deaths is in large part due to the 
development of Highly Active Antiretroviral Therapy (HAART) in 1996, which is a 
cocktail of three or more drugs that target diferent stages of the viral life cycle. HAART 
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transformed HIV/AIDS from a deadly disease to one that is managed for decades as a 
chronic disease. Due to HAART the number of AIDS-related deaths is declining, but the 
prevalence of people living with HIV/AIDS is increasing. Despite the effectiveness of 
current therapies in controling virus replication and prolonging life, HIV-associated 
neurocognitive disorders (HAND) are stil prevalent. Although fewer patients sufer from 
HIV-associated dementia (HAD), the most serious of CNS disorders, a greater number of 
patients are being diagnosed with other milder neurological disorders that affect the 
ability to work and overal quality of life. 
 
HIV Infection Cycle 
 HIV was identified as a member of the Lentivirus genus of viruses [36] named for 
their characteristic long incubation periods prior to manifestation of disease. The first few 
weeks after infection with HIV is caled the acute phase. During this time, individuals 
normaly present with influenza-like symptoms and have high levels of circulating virus. 
These symptoms are accompanied by a rapid and dramatic decline in the number of 
CD4+ T cels. Innate and adaptive immune responses impact infection and the acute 
phase of infection is folowed by an asymptomatic period during which there is an 
increase in CD4+ T cels and lower levels of virus found in the blood. The asymptomatic 
phase can last from months to years. The late stage of disease is AIDS, characterized by a 
dramatic rebound in viral load and a severe decline in number of CD4+ T cels. 
Individuals often succumb to infection by opportunistic pathogens such as bacteria and 
fungi that a person with a healthy immune system could successfuly control. 
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 HIV infects cels of the immune system including CD4+ T cels and cels of the 
myeloid lineage such as monocytes, macrophages and dendritic cels. In the peripheral 
blood and in lymph nodes CD4+ T cels are the major infected cel type. The loss of a 
large population of these immune cels leaves the individual vulnerable to multiple 
opportunistic infections and uncontroled cancer cel growth [37]. In contrast to the 
periphery, monocytes and microglia/macrophages are the major infected cel type in the 
central nervous system (CNS) and these cels are involved in the inflammatory response 
to infection [38]. Infected, activated monocytes are able to cross the blood-brain barrier 
and enter the brain where they mature into perivascular macrophages. These cels support 
productive infection and spread virus to resident macrophages (microglia) and astrocytes 
[38]. Infected cels as wel as bystander cels produce inflammatory cytokines, such as 
interferon beta (IFNβ), the main type I IFN produced in the brain [39]. The role of 
monocytes and macrophages during infection is important to understand, as these cels 
may contribute significantly to the clinical and pathological disease in the CNS of many 
patients with AIDS stage of disease as wel as a large number of HIV-infected individuals 
on HAART who have HIV associated cognitive disorders (HAND).  
 
HIV Restriction factors 
 During acute infection by various types of pathogens, the innate immune response 
fights the invading organism by stimulating the production of antiviral factors, such as 
IFNα/β. This triggers a cascade of factors to aid in clearing the infection. In addition to 
the interferon response, there are host cel restriction factors that also limit HIV/SIV 
infection. Restriction factors are proteins made by the infected cel that are able to target 
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the virus at specific stages of its life cycle and prevent virus spread to naïve cels. There 
are currently four known restriction factors of HIV infection: 1) APOBEC3G 
incorporates into nascent virions where it inhibits integration of the viral genome and/or 
production of functional viral proteins. The mechanism of action is through deamination 
of cytidines in the viral genome, resulting in guanidine to adenine hypermutations [40]; 
2) TRIM5a interacts with the viral capsid protein and disrupts uncoating of the capsid 
[40]. This protein is only active against SIV, as the human analogue contains a mutation 
rendering the protein inactive [40]. 3) Bst-2/Tetherin is the third host restriction factor 
and blocks release of virions from cels by preventing physical detachment from the 
plasma membrane [40]. 4) The most recently discovered host restriction factor to HIV 
infection is SAMHD1. To date, the body of research on this protein suggests that 
SAMHD1 interferes with HIV reverse transcription by depleting the host cel dNTP pool 
[40]. microRNAs (miRNAs) are also host restriction factors of HIV. There has been 
increased interest recently in the effect of miRNAs on HIV infection and pathogenesis. It 
has been demonstrated that there is differential expression of miRNAs in resting vs. 
activated CD4+ T cels [41, 42] as wel as in monocytes and macrophages [43, 44]. Some 
or al of these miRNAs affect celular permissiveness to HIV-1 infection, and have been 
predicted and/or demonstrated to directly target HIV-1 mRNAs and specific miRNAs 
that reduce production of HIV-1 [19, 28-31, 45, 46]. 
 Using varied in vitro assays we identified miRNAs with functional binding sites  
in the SIV genome. Presumably through targeting of SIV mRNAs, the miRNAs cause  
degradation of the SIV transcripts. Because al SIV mRNAs contain an identical 3’ UTR,  
al transcripts are targets for the miRNAs. Reducing the numbers of various transcripts  
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results in an inhibition of virus replication. This work also demonstrates that some of 
these miRNAs regulate cytokine expression, and each miRNA analyzed here is induced 
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Abstract 
Interferon beta (IFNβ) production is an inaugural event in the innate immune 
response to viral infections, with relatively smal fold changes in IFNβ expression 
resulting in the activation of important antiviral signaling cascades. In our rapid 
SIV/macaque model of HIV encephalitis, virus enters the CNS within four days of 
infection, accompanied by a marked IFNβ response that wanes as SIV replication is 
controled. The centrality of IFNβ to the innate antiviral response in the CNS combines 
with the potential inflammatory damage associated with long-term activation of this 
pathway to suggest that IFNβ may be subject to regulatory fine-tuning in addition to 
wel-established transcriptional and message stability mechanisms of regulation. Here, 
we present for the first time evidence that microRNAs, including miRs -26a, -34a, -145, 
and let-7b, may directly regulate IFNβ in human and macaque cels. In primary primate 
macrophages, the main cel type implicated in HIV and SIV infection in the CNS, 
specific miRNAs reduce, while miRNA inhibitors enhance, IFNβ protein production. The 
potential biological significance of this regulation is supported by evidence of an 
apparent negative feedback loop, with increased expression of three IFNβ-regulating 
miRNAs by primate macrophages exposed to recombinant IFNβ or stimulated to produce 





Acute retroviral infection provokes rapid and striking innate immune responses in 
what has been termed a “cytokine storm” [1]. These responses are crucial in determining 
the course of disease, as a delicate balance must be achieved between pro- and anti-
inflammatory processes. The former must be sufficiently ferocious to dampen viral 
replication and impede further infection, while the later are needed to prevent the tissue 
damage inherent in chronic activation of the immune system. In our rapid SIV/macaque 
model of HIV encephalitis, we have shown that both virus and the innate response are 
present in the central nervous system early in acute infection [2-4]. In addition, HIV and 
SIV infection of macrophages induces IFNβ, which in turn evokes downstream antiviral 
responses [2-8]. 
The cytokine IFNβ, with both pro- and anti-inflammatory roles, is the main Type 
I interferon induced during the initial innate response to retroviral infection of the central 
nervous system [9]. IFNβ mRNA and protein levels rise two- and four-fold, respectively, 
in response to viral replication during the acute phase of infection, folowed by a decline 
during the asymptomatic phase [2, 4]. However, these relatively smal fold-changes 
produce multiplicative efects on downstream efectors such as the antiviral protein MxA. 
IFNβ is also crucial for induction of anti-bacterial defenses [10, 11]. 
The pivotal nature of IFNβ and the magnified effects of its differential regulation 
suggest that intricate modulatory mechanisms have evolved to regulate its production. 
Indeed, over several decades, studies have elucidated numerous transcriptional and post-
transcriptional strategies for IFNβ regulation [12]. Maniatis and Whitemore showed that 
an adenylate-uridylate-rich element (ARE)3 in the 3’UTR of the IFNβ mRNA was partly 
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responsible for message degradation [13]. The IFNβ ARE may be the binding site for 
destabilizing ARE binding proteins (AUBPs) such as tristetraprolin [14]. Interestingly, 
the early work on these cis-acting elements in the 3’UTR also presaged an additional 
regulatory possibility: translational modulation by microRNAs (miRNAs)3. 
miRNAs are smal RNA regulatory molecules, on average 22 nucleotides in 
length, that, when integrated into protein complexes known as RNA-induced silencing 
complexes (RISCs), bind to partialy complementary sequences in the 3’ untranslated 
regions of target mRNAs and thereby contribute to gene regulation by inhibiting 
translation and destabilizing transcripts [15, 16]. The human genome may encode over 
one thousand potentialy functional miRNAs [17], and each mature miRNA may have the 
ability to regulate the expression of many genes. An estimated one-half of al protein-
coding transcripts are thought to be subject to miRNA regulation [15]. Among several 
features predicting miRNA regulation of a given 3’UTR is the presence of an AU-rich 
sequence [18] such as that found in the transcripts of IFNβ and many other cytokines 
[19]. AU-rich elements are relatively unstructured and may thereby enhance miRNA 
target site accessibility for miRNA-containing ribonucleoproteins. Recent work has 
identified several potential cytokine miRNA targets [19], with experimental confirmation 
reported for IL-10 [20] and the p35 subunit of IL-12 [21]. Indirect efects of miRNAs on 
cytokines have also been reported [22, 23]. IFNβ is intimately involved in miRNA 
regulation, modulating the expression of numerous miRNAs [24] as wel as the miRNA 
processing enzyme Dicer [25]. To date, no observations of direct effects of miRNAs on 
IFNβ have been published, although indirect effects of miR-146a on the Type I 
interferons have been reported [26, 27]. 
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The importance of IFNβ regulation in the innate immune response to HIV and 
SIV and the presence of an extensive adenylate-uridylate-rich region in the IFNβ 3’UTR 
prompted us to investigate the role of miRNA in direct regulation of IFNβ. We used 
miRNA target prediction algorithms to identify several miRNAs with potential 
recognition sites in the IFNβ 3’UTR, and we screened for miRNAs expressed and 
differentialy regulated in primary macrophages folowing exposure to IFNβ. Of these 
miRNAs, four silenced through the 3’UTR in a reporter assay and affected secretion of 
IFNβ protein by primary macrophages. Treatment of primary macrophages with IFNβ 
upregulates the expression of miR-26a, -34a, and let-7b, suggesting a negative feedback 
loop for the regulation of IFNβ protein. Treatment with polyinosinic:polycytidylic acid 
(poly I:C), a dsRNA stimulator of innate immune responses including Type I interferons, 
similarly resulted in miRNA upregulation, and in a time frame consistent with IFNβ-
mediated regulation. These findings may have significant implications for the fine-tuning 
of the innate immune response during retroviral infection and, potentialy, for the 





Predicted microRNA recognition elements in the IFNβ 3’UTR 
To assess the potential for miRNA regulation of IFNβ, we sought miRNAs that 
could interact with miRNA recognition elements (MREs)3 in the IFNβ 3’UTR. We used 
multiple prediction algorithms, including miRanda [28], RNAhybrid [29], and 
microInspector [30], to search for target sites in the macaque and human IFNβ 3’UTRs. 
We also queried PITA [31], which incorporates 3’UTR folding parameters into its 
predictions. The different target prediction algorithms place varying emphases on seed 
sequence complementarity, heteroduplex free energy of binding, location and size of 
internal loops and bulges, and accessibility of the target site (as predicted by RNA 
folding). 
More than 200 total miRNA-mRNA target duplexes were predicted by these 
algorithms. Most target sites were concentrated in two clusters in the 5’ half of the IFNβ 
3’UTR (Figure 1, boxes). To pare this list of predictions to an experimentaly tractable 
size, we next considered only those predictions shared by three prediction programs, and 
we further reduced the number of candidates by selecting those likely to be expressed in 
macrophages, a cel type of central importance to the innate immune response, HIV/SIV 
CNS disease, and IFNβ production [32]. The likelihood of expression in macrophages 
was assessed according to reported miRNA expression in CD14+ cels [33] and our own 
preliminary results from miRNA microarays with both human and macaque 
macrophages (K. W. Witwer, unpublished data). miRs -26a, -34a, -145, -181a, -198, and 
let-7b were selected for initial study. 
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As is the case for most of the other predicted miRNAs, the MREs for 
macrophage-expressed miRNAs later shown to target the UTR (see below) are located in 
the target-rich 5’ half of the IFNβ 3’UTR (Figure 1). Importantly, only two nucleotide 
differences distinguish the human and macaque 3’UTRs in this region (positions 
indicated by asterisks in Figure 1). Neither of these nucleotides is predicted to bind the 5’ 
seed (6-8 nucleotides) of the targeting miRNA, although a G-A (macaque-human) 
difference in the miR-34a binding site changes a “wobble” G-U base pairing outside the 
seed region to a Watson-Crick interaction, potentialy lending a marginaly more 
favorable binding energy to the human miR-34a:target pair. This near-identity of the 
targeted sequences in human and macaque, combined with the high level of miRNA 
conservation in primates, suggests that observations made in one species translate wel to 
the other. 
 
miRNA mimics silence reporters containing IFNβ 3’UTR sequences 
To examine the functional effects of these miRNAs, we used reporter assays. The 
macaque IFNβ 3’UTR sequence was cloned 3’ to a luciferase reporter gene in a dual 
luciferase expression vector and transfected into HEK-293T cels. Four of the candidate 
miRNAs (miRs -26a, -34a, -145, and let-7b), when added exogenously as miRNA 
mimics, reduced the expression of luciferase in HEK-293T cels (Figure 2a) compared 
with no-miRNA controls and a control Caenorhabditis elegans miRNA with nucleotide 
composition similar to that of the mimics of interest. At 10nM transfected mimic, let-7b 
and an equimolar mixture of the four miRNAs significantly reduced luciferase expression 
(p<0.001). At 40nM, al four miRNAs reduced expression significantly at p=0.01 or 
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lower. miR-34a and the equimolar mixture achieved significant dose-dependent reduction 
in luciferase (p<0.01 and p<0.05, respectively). The apparent lack of dose dependence for 
other miRNAs may indicate that the lower concentration was sufficient to saturate 
binding sites and achieve maximal efect. The equimolar mixture (10nM = 2.5nm each, 
40nM = 10nM each) effected a greater control than any single mimic, suggesting a 
cooperative effect of multiple microRNA recognition element occupancy, as has been 
reported previously [34]. Predicted binding sites for let-7b, miR-26a, and miR-145 
overlap in a region near the 5’ end of the UTR, while the miR-34a MRE is located in a 
separate region, just 5’ to the AU-rich region. 
 To confirm the specific interaction of native miRNAs with the predicted MREs, 
we designed defective MREs with mutations in three (miR-145) or four (-26a, -34a, let-
7b) nucleotides in the 5’ seed-binding region of the MRE (see Supplemental Table I for 
sequences). Mutations were screened in silico (RNAHybrid) in the context of the ful 
3’UTR to avoid inadvertent introduction of a novel consensus sequence for another 
miRNA. Wild-type or seed-mutated MREs coresponding to the four miRNAs were then 
inserted downstream of a fluorescent reporter. These constructs and normalization 
controls were transfected into HEK-293T cels. MRE-containing constructs were silenced 
more efficiently than constructs with seed- mutated MREs (Figure 2B) for al but the 
miR-145 MRE constructs. This effect was significant (p<0.05) for the miR-34a MRE. 
The lower level of significance for the -26a and let-7b MREs and the opposite result for 
the miR-145 constructs suggest several possibilities: the mutations we introduced did not 
fuly abrogate binding of the targeting miRNAs; additional native miRNAs may bind to 
the unmutated regions of the MREs; and/or the introduced mutations may have created 
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seed binding regions for additional miRNAs that were not predicted by our screening 
methods. In addition, comparing the results from Figure 1A and B, additional sites for 
one or more of the four predicted miRNAs present in the ful-length UTR may not be 
represented in the MREs we examined in these experiments. 
 
miRNA mimics reduce, while miRNA antagonists increase, stimulated secretion of 
IFNβ protein 
The potential efect of the four identified miRNAs on IFNβ protein production 
was assessed in primary human macrophages. Human macrophages were chosen for 
these experiments for several reasons. As described above, the near-identities of known, 
expressed macaque and human miRNAs and their respective IFNβ 3’UTRs suggest that 
these miRNAs play the same regulatory roles in humans and macaques. Additionaly, no 
IFNβ ELISAs we tested could reliably detect macaque IFNβ protein in our hands. For 
human protein, the ELISA we used was sensitive from about one through several hundred 
IU/ml with a slightly modified protocol (see Materials and Methods), and the human 
IFNβ response to poly I:C quickly reached the upper end of this range (Figure 3). 
Although macaque macrophages exhibit a robust IFNβ response as measured by qRT-
PCR and downstream products of the IFNβ signaling pathway [7], only low levels of 
protein (in the 1-10 IU/ml range) were detected by ELISA in our experiments. Because 
the amino acid sequences of the respective proteins are highly similar, we hypothesize 
that species-specific glycosylation differences are responsible for the observed lack of 
sensitivity to macaque IFNβ protein. Indeed, changes in two potential N-glycosylation 
sites and one O-linked site appear to be among the macaque-human amino acid 
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differences (glycosylation predictions made by NetNGlyc, 
htp:/www.cbs.dtu.dk/services/NetNGlyc/ and GPP, 
htp:/comp.chem.notingham.ac.uk/glyco/, data not shown) [35]. 
Macrophages were treated or not with two concentrations of an equimolar mixture 
of miRs -26a, -34a, -145, and let-7b. The levels of transfected miRNAs were confirmed 
by qRT-PCR comparison of each miRNA in pre- and post-transfection macrophages 
(data not shown). Poly I:C RNA (50 ug/ml) was added to the culture medium to stimulate 
production and secretion of IFNβ protein, and protein levels were measured by ELISA 
(Figure 3). At 24 hours post-stimulation, the level of IFNβ protein secreted by 
macrophages treated with 10 or 40 nM miRNA mimics (normalized to no-miRNA, poly 
I:C-treated control) was reduced by approximately 35% and 80%, respectively, compared 
with stimulated controls treated with a control miRNA. 
miRs -26a [36, 37], -34a [38-40], -145 [41], and let-7 family members [42, 43] 
have reported efects on cel death processes in cancer, and promotion of apoptosis by 
transfected cels is one explanation for lower IFNβ production by miRNA-transfected 
cels. Although no excess cel death was observed in the macrophages transfected with 
miRNA mimics, the short time course of these experiments might have limited detection. 
Accordingly, we transfected macrophages with miRNA mimics and control RNA (CmiR) 
and measured cel death at three and 10 days post-transfection by trypan blue exclusion. 
No differences in live cel counts were observed between untreated cels, transfection 
reagent-treated, CmiR-, and miRNA-transfected cels (Supplemental Figure 1). Thus, it is 
unlikely that the apparent miRNA-mediated downregulation of IFNβ protein is due to 
promotion of apoptosis by the transfected miRNAs. We also conclude that the pro-
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apoptotic effects observed in the cancer literature may not triggered by these same 
miRNAs in the regulatory environment of healthy primary cels. 
Beyond cel death, exogenous miRNA mimics could have other unintended 
indirect or off-target consequences [44], including saturation of the miRNA processing 
machinery, stimulation of intracelular signaling pathways, and miRNA-mediated up- or 
down-regulation of transcripts whose products could affect IFNβ production. As a result, 
we sought to inhibit native levels of the four identified miRNAs using miRNA antagonist 
oligos that were chemicaly modified to enhance stability and reduce off-target efects. 
These antagomiRs bind to their cognate miRNAs and prevent association with target 
mRNAs.  
The transfected antagomiRs, both singly and in equimolar mixture, increased the 
amount of IFNβ secreted by primary macrophages exposed to poly I:C stimulation 
(Figure 4). At 20 nM added antagonist, the effects of miR-34a and let-7b antagonists 
were significant, as were those of an equimolar mixture of the four miRNAs (al, 
p<0.05). Efects of miR-26a and miR-145 approached significance (p<0.07). At 100 nM, 
miR-26a, miR-34a, and let-7b produced significant effects (p<0.01), while miR-145 
antagonist approached significance (p<0.06). We observed an apparent lack of dose-
dependence with the equimolar mixture of antagonist, suggesting that a saturation of 
some native cognate miRNA may occur at the lower concentration. 
 The antagonist-mediated increased levels of IFNβ protein do not appear to result 
from increased levels of IFNβ mRNA. Using quantitative real-time RT-PCR and a ΔΔCt 
normalization method as described previously [4], we compared IFNβ mRNA levels from 
primary macrophages treated or not with miRNA antagonists and poly I:C. No significant 
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differences were found between transcript levels in antagonist-treated and -untreated 
macrophages (R2=0.0035; Supplemental Figure 2). 
 
A negative feedback mechanism: IFNβ stimulates expression of modulating miRNAs
 We next assessed the potential biological significance of these results by profiling 
miRNA expression in primary macaque macrophages treated or not with recombinant 
IFNβ. Preliminary results from miRNA microarrays had indicated upregulation of three 
of the four IFNβ-targeting miRNAs upon stimulation with recombinant IFNβ (data not 
shown). We used a quantitative and mature miRNA-specific method, stem-loop qRT-
PCR [45], to measure the levels of miRNAs in primary macaque macrophages treated or 
not with recombinant IFNβ. Three of the four miRNAs were upregulated in response to 
IFNβ, and the results suggest the possibility of distinct temporal regulation paterns for 
different miRNAs in response to IFNβ (Figure 5). miR-26a was upregulated by two hours 
post-IFN treatment, and levels continued to increase through eight and 24 hours. In 
contrast, miR-34a increased by 2 hours, was lower at eight hours, and increased again by 
24 hours post-treatment. let-7b initialy increased dramaticaly, but decreased to 
background levels at subsequent time points. Consistent modulation was not observed 
with miR-145.  
 To address whether native IFNβ protein, produced in response to a stimulus such 
as exogenous dsRNA, could reproduce the efects seen with recombinant protein, we 
treated primary human macrophages with poly I:C and sampled culture supernatants and 
total celular RNA at one, three, eight, and 24 hours post-treatment. ELISA for secreted 
IFNβ (Figure 6A) revealed that at one hour, protein levels were at or below the limit of 
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detection and did not difer from those of untreated cels. IFNβ was detectable by thre 
hours; a large increase was observed by eight hours. IFNβ remained elevated through 24 
hours post-treatment. 
 Modulation of the three miRNAs that responded to recombinant IFNβ was 
measured by stem-loop qRT-PCR (Figure 6B). Increased miR abundance in poly I:C-
treated cels, compared with untreated cels, occurred only at or after the first detection of 
IFNβ protein, providing further evidence that IFNβ mediates the abundance of IFNβ-
targeting miRNAs through a negative feedback mechanism. miR-26a folows a steady 
increase like that elicited by recombinant IFNβ. Similarly, let-7b increases initialy and 
then declines. For both miR-26a and let-7b, early upregulation in the presence of initialy 
low IFNβ protein levels suggests exquisite sensitivity of these miRNAs to IFNβ. The 
miR-34a response, in contrast, does not appear until much later, when IFNβ protein is 
present at over 100 IU/ml.  
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Discussion  
Our results suggest that miRNAs -26a, -34a, -145, and let-7b may modulate 
expression of IFNβ, thereby influencing innate immunity from the earliest responses to 
viral infection. For -26a, -34a, and let-7b, this modulation may be exerted directly 
through miRNA recognition elements in the IFNβ 3’UTR. Although we used macaque 
IFNβ sequences to evaluate direct interactions, our results appear to apply as wel to 
human IFNβ, as supported by ELISA experiments with human macrophages. Based upon 
target predictions and the sequences of human and macaque IFNβ, we observe that 
although the human and macaque 3’UTRs have only 94% sequence identity, al but two 
of the nucleotide differences are found in the relatively MRE-devoid AU-rich 3’ half of 
the UTR. Also, miRNA binding is thought to be determined largely by perfect or near-
perfect target complementarity to a “seed” region of six to eight nucleotides at the 5’ end 
of the miRNA, and neither of the two macaque-human nucleotide differences in the 5’ 
half of the IFNβ 3’UTR is found in a relevant predicted seed-binding sequence. The 
human and macaque miRNA sequences we have examined are identical. Many miRNAs 
and IFNβ are conserved in vertebrates, implying that the identified miRNA-IFNβ 
interactions may not be restricted to primates. 
The potential biological significance of miRNA regulation of IFNβ in primates 
receives in vivo suport from our SIV/macaque model of HIV encephalitis, as three of the 
four putative IFNβ-modulating miRNAs are upregulated in the CNS at 42 days post-SIV 
infection (K. W. Witwer, unpublished observations) and may contribute to maintaining 
the low levels of IFNβ measured at this time point [4]. Moreover, biological significance 
is also supported by the apparent presence of a negative fedback loop. Three of the 
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identified IFNβ-modulating miRNAs are upregulated in response to both recombinant 
IFNβ and poly I:C-stimulated production of native IFNβ in primary macrophages, 
suggesting that a biological feedback mechanism may govern the interaction of miRNAs 
and IFNβ: IFNβ triggers production of miRNAs capable of binding the IFNβ transcript 
and interfering with protein production.  
To confirm that IFNβ itself is necessary for upregulation of miRs -26a, -34a, and 
let-7b, we performed several experiments with neutralizing antibody to IFNβ. Curiously, 
the neutralizing antibody appeared to potentiate, not abrogate, the IFNβ response (data 
not shown), a result consistent with a recent report [46] wherein IFN-neutralizing 
antibodies are shown to elicit or potentiate Type I IFN responses in endothelial cels and 
PBMCs. The reported efects are dependent on IFN binding and the presence of the Fc 
portion of the antibody. In light of these results, future experiments using Fab 
neutralizing antibody fragments may further clarify the role of IFNβ in miRNA 
regulation. 
Since both miR-26a and let-7b are expressed at relatively and constitutively high 
levels in many cel types, these miRNAs may exert a constant inhibitory pressure on 
IFNβ levels even in the absence of miRNA upregulation [47]. 
Of note, the two IFNβ-regulating miRNAs, -26a and -34a, which are increased 
from two through 24 hours after IFNβ treatment of primary macrophages, are both 
implicated in cancer and have been studied in the clinic or as potential treatment targets. 
miR-26a has recently been shown to affect cel cycle progression and used as a therapy 
for liver cancer in an animal model [36]. It may be modulated diurnaly [48], and among 
its targets are PTEN and the Ezh2 histone methyltransferase [49-52]. miR-34a has been 
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characterized as a p53-regulated miRNA involved in cel cycle progression and apoptosis 
[53] and as part of a positive feedback loop involving p53 and SIRT1, a direct target of 
miR-34a [54]. Like miR-26a, -34a is implicated in cancers, and its expression has been 
studied in a clinical trial of chronic lymphocytic leukemia [55]. Our results indicate an 
additional mode of action for these important miRNAs. 
The mechanisms governing transcriptional and post-transcriptional regulation of 
IFNβ-regulating miRNAs demand experimental study, but we note here that the genomic 
context of the primary transcripts for miR-26a, miR-34a, and let-7b suggests several 
regulatory strategies. The start sites and promoters for these transcripts are found in or 
near CpG islands [56, 57], implying epigenetic control. Numerous predicted and several 
experimentaly validated transcription factor binding sites are also present and could 
contribute to regulation. 
Of particular interest are two transcription factors, p53 and Stat3. The connection 
between IFNβ and p53 signaling has recently been characterized [58]. miR-34a [38] is a 
reported p53 transcriptional target, and the let-7b coding region contains a p53 binding 
site [56]. It is thus possible that p53 mediates the IFNβ-stimulated upregulation of these 
two miRNAs. 
We further propose that rapid downregulation of let-7b, folowing a brief post-
IFNβ surge, may be effected by Stat3, a transcription factor involved in interferon 
signaling. Stat3 has been reported as an activator for miR-21 expression [59], but a single 
transcription factor can have opposite efects in diferent setings [60]. Stat3 has been 
implicated as a negative regulator of IFN-mediated antiviral responses [61] and, 
reminiscent of its reported role in downregulating E-Cadherin expression [62], Stat3 may 
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be responsible for repressing let-7b folowing initial IFNβ-mediated transcriptional 
upregulation. Interestingly, the predicted Stat3 binding site is actualy within the 
sequence encoding the mature let-7b. 
Regulation of innate immune responses, and particularly of IFNβ, has been 
demonstrated to occur at multiple levels; however, miRNAs have not previously been 
implicated directly in this regulation. We demonstrate for the first time that secretion of 
IFNβ from primary macrophages is reduced by miRNAs that recognize sequences in the 
3’UTR of the mRNA.  
The regulation of IFNβ by miRNAs as demonstrated in these studies is consistent 
with our broad hypothesis that a cytokine pivotal in downstream signaling for innate 
immunity requires regulation at every level of expression. IFNβ is among the first genes 
induced in response to, e.g., retroviral infection, and it then regulates expression of 
signaling pathways, transcriptional regulation, and the induction of antiviral cascades. 
Two- to four-fold changes in the level of IFNβ mRNA and protein initiates signaling 
cascades that ultimately magnify the IFNβ effect thousands to ten thousands-fold. 
Because these downstream changes include potent inflammatory cytokines, the cel has 
evolved highly sensitive controls, both positive and negative [63], to keep them in careful 
balance, and previously unknown mechanisms continue to be discovered [64]. miRNA 
regulation of the IFNβ protein is now added to transcriptional control, message stability, 
and protein stability as an effector of IFNβ regulation. 
We note that the miRNAs reported here are unlikely to be the only miRNA 
species to affect the IFNβ 3’UTR, for at least two reasons. First, despite considerable 
advances and much thoughtful work in the development of prediction algorithms, no 
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single method or combination of methods is yet completely reliable. Second, we observe 
that most studies in the current literature make the same assumption that guided our 
selection of candidate IFNβ regulatory miRNAs: namely, that regulation of a message by 
a smal RNA presupposes (or is suggested by) regulation of the miRNA itself. This is 
probably an oversimplification. Modulation of gene expression by miRNA is unlikely to 
stand alone, but, rather, is probably part of a constelation of regulatory mechanisms. A 
change in any one of the parts of this system could place a greater burden on another arm 
of the system without corresponding up- or downregulation of the respective components. 
Since miRNA-mediated regulation without differential expression of the regulating 
miRNAs is passed over by candidate screening, such as in our methods, it is possible that 
additional smal RNA regulators of IFNβ await discovery. 
With an increasing number of innate immune system components showing 
evidence of miRNA targeting, the demonstrated potential of miRNA-based therapeutics 
[36, 65] provides a promising new possibility for modulation of the body’s first line of 










Materials and Methods 
MicroRNA target predictions and in silico genomics 
Sequences of known and predicted mature human and macaque miRNAs were 
obtained from the microRNA Registry at miRBase, htp:/www.mirbase.org/ [66-68]. 
IFNβ sequences were from the NCBI Nucleotide database, htp:/www.ncbi.nlm.nih.gov/. 
The prediction algorithms miRanda [28], RNAhybrid [29], microInspector [30], and 
PITA [31] were used to search for miRNA target sites in the macaque and human IFNβ 
3’UTRs. Where applicable, miRNA-target seed sequence matches were alowed to 
include G:U wobble and up to one mismatch. Human and macaque IFN-beta proteins 
were found to be 95% identical and 97% similar by BLAST 
(htp:/blast.ncbi.nlm.nih.gov/Blast.cgi for NP_001129267.1 and NP_002167.1). miRNA 
primary transcript sequences were obtained from the University of California, Santa Cruz 
genome browser (htp:/genome.ucsc.edu/) [56]. The presence of CpG islands and 
transcription factor binding sites was assessed with the UCSC browser tracks “CpG 
Islands” [57] and “HMR Conserved Transcription Factor Binding Sites” by Weirauch 
and Raney. 
 
Cels and Reagents 
Monocyte-derived macrophages were isolated from pigtailed macaques (Macaca 
nemestrina) and from human subjects as previously described (7). The Johns Hopkins 
Institutional Review Board reviewed and approved al human and animal studies, and al 
samples were obtained in accordance with IRB protocols. Human cels were used in 
experiments involving ELISA quantitation of IFNβ protein, as the ELISA reagents 
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available are relatively insensitive to macaque IFNβ (in our hands). HEK-293T cels were 
acquired from the America Type Culture Colection (ATCC, Manassas, VA). miRNA 
mimics and antagonists were purchased from Ambion (Austin, TX) or 
Dharmacon/Thermo Fisher Scientific (Waltham, MA). Negative control RNA was the 
miRIDIAN microRNA Mimic Negative Control #1 from Dharmacon (Sequence: 
UCACAACCUCCUAGAAAGAGUAGA), screened against the human and macaque 
genomes by using the BLAST-like alignment tool [69]. Oligonucleotides for cloning 
were obtained from IDT (Coralvile, IA; see Supplemental Table I for sequences). 
Recombinant IFNβ (PBL-Interferon Source, Piscataway, NJ) and 
polyinosinic:polycytidylic acid (poly I:C, Amersham/GE Healthcare, Piscataway, NJ), 
were used at 100 U/ml and 50 µg/ml, respectively. 
 
RNA isolation  
Total RNA was isolated and purified by the Trizol method (Invitrogen, Carlsbad, 
CA) or miRvana kit (Ambion) according to the manufacturer’s protocol. Concentration 
and purity were measured using a NanoDrop spectrophotometer (ND-1000 with V3.5.2 
software, Thermo Fisher Scientific) and denaturing RNA gels, which were imaged by an 
Eagle Eye detection system (Stratagene, La Jola, CA). 
 
Plasmid vectors 
The 3’UTR of the pigtailed macaque IFNβ mRNA was generated by PCR and 
inserted between the XhoI and NotI restriction sites downstream of the Renila luciferase 
gene of the dual luciferase vector psiCHECK-2 (Promega, Madison, WI). Sense 
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oligonucleotides containing the predicted wild type and mutated microRNA recognition 
elements of the IFNβ 3’UTR (for miRNAs let-7b, miR-26a, miR-34a, and miR-145) were 
annealed with corresponding antisense oligos and inserted between the XhoI and KpnI 
restriction sites downstream of the in pEGFP-C1 (BD Clontech, Palo Alto, CA). Oligo 
sequences are provided in Supplemental Table I. 
 
Luciferase assays 
HEK-293T cels were co-transfected with psiCHECK-2 (with or without the IFNβ 
3’UTR) and miRNA mimics using Lipofectamine 2000 (Invitrogen). Cel lysates were 
prepared 24 hours post-transfection and luciferase levels were measured using an Ascent 
Fluoroskan fluorometer and the Dual Luciferase Reporter Assay System (Promega). 
 
Fluorescence assay 
HEK-293T cels were cotransfected with specific pEGFP-C1 constructs and a 
transfection control, pdsRed-N1 (BD Clontech). Fluorescence expression was measured 
24 hours later with a Typhoon scanner (Amersham/GE Healthcare, Piscataway, NJ) and 
analyzed by ImageQuant software (Amersham). For each transfection, green fluorescence 
intensities were normalized by red fluorescence. 
 
IFNβ ELISA 
Human macrophages were transfected with miRNA mimics or antagonists 
(Dharmacon, Qiagen, or Ambion) using HiPerFect (Qiagen). After six hours, cels were 
washed with PBS and refed with media containing 50 µg/ml poly I:C. Culture 
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supernatants were colected after 24 hours, and IFNβ levels were measured by ELISA 
(FujiRebio - Invitrogen) according to the manufacturer’s protocol but with an overnight 
primary incubation at 4oC to increase sensitivity. ELISA results were obtained using a 
Microplate Reader, Model 680 (Bio-Rad, Hercules, CA).  
 
miRNA and IFNβ mRNA qRT-PCR 
Macaque macrophages were treated with 100 U/ml of IFNβ (PBL), and cels were 
harvested at 2, 8, and 24 hours post-treatment for RNA isolation. Levels of mature 
miRNAs were measured by individual qRT-PCR assays (Applied Biosystems, Foster 
City, CA) per manufacturer’s protocol, using 10 ng of total template RNA. Quantitative 
RT-PCR for IFNβ mRNA was performed as described previously [4]. 
 
Statistical analysis 
Analysis was performed using Microsoft Ofice 2004 Excel, including the Data 
Analysis add-on (Microsoft, Redmond, WA), and GraphPad Prism, version 6 (GraphPad 
Software, San Diego, CA). For Student’s t-test, two-tailed tests were performed and equal 
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Figure 1. Predicted miRNA recognition elements in the IFNβ 3’UTR. 
miRNA prediction algorithms were used to evaluate the likelihood of miRNA binding in 
the IFNβ 3’UTR. More than 200 hits (3’ ends represented as diamonds along the ~200 nt 
3’ UTR) were filtered by algorithm overlap and expression analysis, with six miRNAs 
(including the four forming the duplexes shown, which were later validated) selected for 
further analysis. The 5’ half of the 3’UTR contains most of the predicted miRNA 
recognition elements (MREs), including those for the four selected miRNAs, which are 
further concentrated in two areas as indicated by black-outlined boxes. The 3’ half of the 
UTR is AU-rich (shaded region) and contains relatively few predicted target sites. MREs 
for miRs -145, -26a, and -let-7b overlap in the first box, while the predicted -34a MRE 
starts at nt 50 of the 3’UTR. From human to macaque, only two nucleotide changes are 
found in the target-rich region (indicated by asterisks). Neither affects seed-binding 
regions though to be needed for miRNA interaction. Duplexes are shown with the target 
sequence above the miRNA sequence. G:U wobble (‘:’) and Watson-Crick pairing (‘|’) 
are indicated. A macaque to human transition in the -34a binding site (parentheses) 


















Figure 2. miRNAs directly target sequences in the IFNβ 3’UTR. 
miRNA mimics reduce luciferase expression from an IFNβ 3’UTR-containing dual 
firefly/Renila luciferase reporter vector (A). Normalized luciferase expression is reduced 
in HEK-293T cels transfected with specific miRNA mimics and equimolar mixtures of 
the four indicated miRNAs, but not in cels transfected with a control miRNA (CmiR). 
Each condition is presented relative to a no-miRNA control, set equal to one. Eror bars 
are SEM from three independent experiments. Individual predicted IFNβ miRNA 
recognition elements cloned downstream of GFP suppressed GFP expression in HEK-
293T cels, but three of four mutated MREs relieved this suppression (B). Fluorescence 
intensity is displayed as the ratio of mutant to wild-type MREs, normalized to red 




Figure 3. miRNA mimics inhibit IFNβ protein secretion by primary macrophages. 
A 10 or 40 nM equimolar mixture of four miRNAs (miRs -26a, -34a, -145, and let-7b) or 
control miRNA was transfected into primary human macrophages, which were then 
treated with 50 µg/ml poly I:C to stimulate IFNβ production. 24 hours post-treatment, 
supernatants were colected from no-miRNA controls as wel as miRNA- (miR mix) and 
control miRNA-transfected (CmiR) macrophages; IFNβ levels were measured by ELISA. 
Levels from control miRNA-treated samples are depicted normalized to poly I:C-treated, 












Figure 4. miRNA antagonists relieve native miRNA inhibition of IFNβ secretion. 
Primary human macrophages were transfected with specific or control antagomiRs, 
chemicaly modified to enhance stability and to hinder recognition by intracelular RNA 
sensors and subsequent activation of the interferon pathway. Macrophages were treated 
with poly I:C (50 µg/ml). After 24 hours, supernatants were colected and secreted IFNβ 
protein levels were measured by ELISA. Results from four independent experiments with 
macrophages from three donors are shown relative to IFNβ levels of poly I:C treated, no-












Figure 5. IFNβ treatment of primary macrophages modulates three of four IFNβ-
regulating miRNAs. 
Primary macrophages from two pigtail macaque donors were treated with 100 U/ml 
recombinant IFNβ, with RNA colected at two, eight, and 24 hours post-treatment. 
miRNA levels for miRNAs -26a, -145, -34a, and let-7b were measured on al samples in 
triplicate by stem-loop qRT-PCR, including no reverse transcriptase and no template 
controls. The results were analyzed by ∆∆Ct, with normalization to U6 snRNA levels and 









Figure 6. Poly I:C treatment of macrophages induces IFNβ and miRNA production 
consistent with IFNβ-mediated miR upregulation. 
Primary human macrophages were treated with 50 µg/ml poly I:C. IFNβ response (A) 
was detectable by ELISA by three hours and increased through 24 hours post-treatment. 
Limit of detection (about 1 IU/ml) is shown as a line. Results are from two donors, 
measured in duplicate. miRs -26a, -34a, and let-7b were quantified by stem-loop qRT-
PCR (B). Results are fold change of treated over untreated macrophages at each time 




Supplemental Figure 1. Macrophage viability is unafected by miRNA transfection. 
Primary macrophages were transfected with 10 or 40 nM miRNA mixture (miRs -26a, -
34a, -145, and let-7b), 10 or 40 nM miRNA control (CmiR), treated with transfection 
reagent alone (HiPerFect), or left untreated. Viability was assessed by trypan blue 






Supplemental Figure 2. miRNA antagonist effects on IFNβ protein are not due to 
changes in IFNβ transcript levels. 
Primary human macrophages (treated as described in the legend to Figure 3) were 
harvested at 24 hours after treatment with 50 µg/ml poly I:C. RNA was purified from al 
samples treated with poly I:C and transfected with antagonists or control anatagonist. 
IFNβ mRNA levels were measured by qRT-PCR and results were analyzed by the ∆∆Ct 
method, with normalization of antagonist-treated sample levels to 18S rRNA levels and 
antagonist control-treated cels. IFNβ mRNA levels were compared with corresponding 
supernatant protein levels as determined by ELISA (Figure 3). There was no apparent 









The IFN 3'UTR was amplified from M. nemestrina genomic DNA by PCR, digested with 
Xho I and Not I, and inserted into psiCHECK-2. 
 
3'UTR individual MREs 
26a MRE-F TCGATAGCCTGTGCCTCTGGGACTGGACGATATCGTAC 
26a MRE-R GATATCGTCCAGTCCCAGAGGCACAGGCTA 
26a Mut-F TCGATAGCCTGTGCCTCTGGGAGTGCTGGATATCGTAC 
26a Mut-R GATATCCAGCACTCCCAGAGGCACAGGCTA 
 
145 MRE-F TCGACTCTGGGACTGGACAGATATCGTAC 
145 MRE-R GATATCTGTCCAGTCCCAGAG 
145 Mut-F TCGACTCTGGGACACCTCAGATATCGTAC 
145 Mut-R GATATCTGAGGTGTCCCAGAG 
 
34a MRE-F TCGATCAACCGGCAGATGCTGTTTGATATCGTAC 
34a MRE-R GATATCAAACAGCATCTGCCGGTTGA 
34a Mut-F TCGATCAACCGGCAGATCGACATTGATATCGTAC 
34a Mut-R GATATCAATGTCGATCTGCCGGTTGA 
 
7b MRE-F TCGAAGATCTCCTAGCCTGTGCCTCTGATATCGTAC 
7b MRE-R GATATCAGAGGCACAGGCTAGGAGATCT 
7b Mut-F TCGAAGATCTCCTAGCCTGTGGGAGTGATATCGTAC 
7b Mut-R GATATCACTCCCACAGGCTAGGAGATCT 
 
Oligos were annealed and inserted into pEGFP-C1 digested with XhoI and KpnI; a 
unique EcoRV site was placed into the insert to facilitate screening. Al constructs were 
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Abstract 
 Long-lived HIV-1 reservoirs include tissue macrophages. Monocyte-derived 
macrophages are more susceptible to infection and more permissive to HIV-1 
replication than monocytes for reasons that may include the effects of diferent 
populations of miRNAs in these two cel classes. Specificaly, miRs-28-3p, -150, - 
223, -198, and -382 exert direct or indirect negative effects on HIV-1 and are 
reportedly downmodulated during monocyte-to-macrophage differentiation. Here, 
new experimental results are presented along with reviews and analysis of published 
studies and publicly available datasets, supporting a broader role of miRNAs in HIV-1 
restriction than would be suggested by a simple and uniform downregulation of anti- 
HIV miRNAs during monocyte-to-macrophage diferentiation. Although miR-223 is 
downregulated in macrophages, other putatively antiviral miRNAs are more abundant 
in macrophages than in monocytes or are rare and/or variably present in both cel 
classes. Our analyses point to the need for further studies to determine miRNA 
profiles of monocytes and macrophages, including classic and newly identified 
subpopulations; examine the sensitivity of miRNA profiling to cel isolation and 
differentiation protocols; and characterize rigorously the antiviral effects of previously 
reported and novel predicted miRNA-HIV-1 interactions in cel-specific contexts. 
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Introduction 
 A chalenging obstacle to eradication of HIV is the latent reservoir: long-lived 
cels harboring relatively quiescent integrated HIV. The ability to identify and clear these 
reservoirs wil form the basis for efective, curative strategies [1–4]. The best 
characterized reservoir is the resting CD4+ T-cel [5,6]. However, multiple macrophage 
populations in tissues are also important reservoirs [7–9]. While HIV-1 infection and 
replication is restricted in monocytes, permissivity increases as monocytes differentiate 
into macrophages [10,11]. The mechanisms underlying this diference are incompletely 
understood, but one proposed component is the microRNA complement of macrophages, 
which has been reported to diverge from that of monocytes [12–14]. 
 The details of the monocyte-to-macrophage miRNA divergence in relation to 
HIV-1 replication, i.e., which miRNAs are differentialy regulated, and in what direction, 
have been a mater of interesting and potentialy conflicting results. In this paper, we first 
assess the level of concordance and discordance between the various publications 
examining miRNA profiles during monocyte-to-macrophage differentiation. We then 
present a new set of miRNA profiling data that includes biological replicates of primary 
monocytes and macrophages from three human donors. Together, these findings are 
assessed in relation with previously published work and other publicly available datasets 
to derive conclusions about the consequences of monocyte differentiation-related miRNA 
regulation for HIV-1 replication and to identify important questions for continuing 
research in this area. 
 In 2009, X. Wang et al. reported a pronounced downregulation of several 
putatively anti-HIV-1 miRNAs as monocytes differentiated into macrophages [13]. The 
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authors suggested that miRNAs that are abundant in monocytes act to inhibit HIV-1, and 
that when levels of these miRNAs are reduced during differentiation into macrophages, 
HIV replicates more productively. In contrast, Coley et al. reported no downmodulation 
of these or other miRNAs in macrophages compared with monocytes [15]. Dicer, the 
major cytoplasmic miRNA processing enzyme [16], was not detected in monocytes, 
alowing only limited miRNA production through the PIWI alternative processing 
pathway [15,17]. Differentiation of monocytes into macrophages was accompanied by 
Dicer production and concomitant increases in miRNA levels [15,17]. Coley et al. 
posited that relief of HIV-1 restriction in the presence of larger amounts of miRNAs in 
macrophages could be achieved through repressive actions of viral proteins (Vpr, Nef, 
Tat) on Dicer. Coley et al. did not report diferential regulation under any conditions—
differentiation or HIV-1 infection—of any of the miRNAs reported to be downregulated 
by X. Wang et al. However, it is unclear that definitive conclusions should be drawn 
from these apparent contrasts, since the global miRNA profiling in the Dicer study [15] 
was done using PMA-induced differentiation of the monocytic U937 line, while X. Wang 
et al. examined four miRNAs in primary cels [13]. 
 Profiling studies of PMA-induced cel line differentiation models ofer important 
points of comparison to these HIV-1-focused studies. In 2011, a hybridization study of 
miRNA profiles before and after PMA-induced U937 differentiation was published by J. 
Wang et al. [18]. Biological triplicates alowed statistical analysis, dye swap experiments 
for two replicates permited elimination of artifacts based on dye bias, selected results 
were confirmed by individual qPCR reactions, and the authors reported their raw data and 
methods per MIAME requirements [19,20]. Of 44 differentialy regulated miRNAs, 12 
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were downregulated in differentiated U937 cels. Of the 32 upregulated miRNAs [18,20], 
approximately ten (see Table 1) were found among the 64 upregulated miRNAs reported 
by Coley et al. [15]. Additionaly, two putative anti-HIV miRNAs were up-, not 
downregulated. Li et al. included qPCR evidence for significant downregulation in the 
U937 system of miRs-15a, -16, and -223, but only slight changes in miR-142-5p or let-7 
family members [21]. Using another differentiation model—PMA stimulation of THP-1 
cels—Forrest et al. performed hybridization microarrays for three biological replicates at 
a zero hour time point and at several time points post-PMA treatment; next generation 
sequencing was also done, and the data were deposited with CIBEX [22–24]. At 96 hours 
post-PMA treatment, 23 miRNAs were diferentialy regulated by three-fold or more. 
Folowing PMA treatment of the HL-60 line, Chen et al. [25] and Kasashima et al. [26] also 
observed differential regulation. 
 The results of our comparisons of these experiments are listed in Table 1. We 
posit that judicious comparison of these results is feasible despite differences in specific 
myeloid line, PMA concentration, and differentiation time. PMA concentrations (16–300 
nM) were within the relatively wide range customarily employed in these models, and 
although RNA was colected at time points from 24 to 96 hours, differential expression of 
miRNAs begins within hours of PMA treatment and remains largely constant from 24 to 
96 hours in the THP-1 model [22]. Thus, although culture conditions may very wel 
affect results, commonly regulated miRNAs may be considered robust correlates of 
differentiation in these models. 
 The first miRNA profiling of primary monocyte-to-macrophage differentiation 
was reported in 2007 by Fontana et al., who generated monocytic cultures from adult 
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CD34+ hematopoietic progenitor cels and differentiated monocytes into mature 
macrophages in the presence of macrophage colony stimulating factor (M-CSF) [12,27]. 
As confirmed by quantitative real-time PCR and Northern blots, miRs-17, -20a, and -
106a (components of the miR-17/92 clusters) were downregulated during diferentiation 
of unilineage monocytic cultures [12]. Members of this group also reported evidence for 
involvement of miR-424 in the monocyte-to-macrophage differentiation process [28]. 
Fontana et al. cited unpublished microarray studies that formed the basis of their work. 
There do not appear to have been subsequent publications or database submissions based 
on this dataset, which would certainly be a valuable addition to the available evidence on 
the role of miRNA in monocyte-to-macrophage diferentiation. 
 Indeed, to our knowledge, the only monocyte-to-macrophage differentiation 
miRNA study to date that has examined primary cel profiles with biological replicates, 
global miRNA profiling, and PCR verification was presented by Sung and Rice in 2009 
[14]. These investigators, like most teams that examined cel lines, did not find uniform 
up- or downregulation of miRNAs. Rather, after gathering hybridization microaray 
profiles of monocytes and MDM derived from two human donors, they reported that, 
while most miRNAs maintained relatively constant expression, there were 
several examples of differential regulation in either direction (nine up and thirteen down) 
[14]. Interestingly, these results also confirmed one of the four downregulated miRNAs 
(miR-223) reported by X. Wang et al. in primary cels [13], while suggesting that 
another, miR-150, might be upregulated in some macrophages. 
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Results and Discussion 
2.1. Diferential Regulation of miRNAs: New Evidence 
 The disparities in the published results in the HIV-1 field and in the general 
monocyte differentiation literature on cel lines and primary cels prompted us to conduct 
further profiling studies with monocytes and monocyte-derived macrophages from 
human donors. We began with an experiment using cels from two donors (labeled 
throughout as donors I and II), performing anti-CD14 bead-based isolation of monocytes 
from PBMCs. Isolated monocytes were >98% pure and viable as assessed by flow 
cytometry. Total RNA was isolated from the isolated monocytes. At the same time, 
PBMCs from the same donors were differentiated into monocyte-derived macrophages 
(MDM) for seven days [29]. Total RNA was then purified from MDM. To minimize the 
possibility of dye-related artifact (Cy3 signals are often slightly stronger than those for 
Cy5, and Cy5 results are disproportionately affected by environmental conditions such as 
atmospheric ozone levels [30,31]), Cy3 and Cy5 dye-swap hybridizations were 
performed for each sample with hybridization microarrays. Because microarray 
experiments are also susceptible to batch effects [31,32] and may thus include artifactual 
elements [33], we repeated the experiment several months later with cels from a third 
donor to assess the robustness of results from diferent batches. Finaly, we performed the 
same differentiation with cels from a leukopack that was shipped to our laboratory 
overnight; at least 24 hours elapsed between the initial blood draw and isolation of 
PBMCs and monocytes. We have previously observed that cel activation states differed 
between shipped leukopacks and freshly obtained blood [34], and we wished to observe 
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whether any diferential expression was sufficiently robust to be seen in leukopack-
derived cels, as wel. 
 Results are presented in Figure 1, Table 2, and on a miRNA-by-miRNA basis 
below. Many of our results are consonant with previous findings (Figure 1 and Table 2, 
Group I [14]), despite several differences between our cels and culture conditions and 
those used in other studies, but we also find evidence for differential regulation of 
miRNAs heretofore unreported in monocyte-to-macrophage differentiation (Table 2, 
Groups II and II). We focus initialy on miRNAs that have putative direct or indirect 
anti-HIV-1 roles; the genomic neighborhoods of these miRNAs are presented in 
Supplementary Table 1. 
 
2.2. miR-29 Family 
 miR-29a is the only miRNA reported by at least two groups to have a direct effect 
on HIV-1 expression [35–37] on the basis of reporter assays in which HIV-1 sequences 
were included in a reporter plasmid and exposed to miRNAs, including conclusive 
evidence of RNA-RNA interaction from experiments in which the putative target site was 
mutated [36]. miR-29a is encoded with miR-29b in one transcript on chromosome 7, 
while another copy of miR-29b is co-transcribed with miR-29c from a cassete on 
chromosome 1. Because miR-29b and miR-29c share an identical seed sequence and are 
otherwise highly similar to miR-29a, it is likely that al family members would exert 
some effect on HIV. Along these lines, Ahluwahlia et al. presented evidence for direct 
regulation by miR-29b [35], while Chiang et al. reported indirect influence through miR-
29b-mediated regulation of Cyclin T1 [38]. Finaly, our group has shown that miR-29 
 67 
family members interact directly with simian immunodeficiency virus (SIV) in 
macrophages [39,40] by means of reporter/mutation and functional assays. 
 In our studies, miR-29a was more abundant in macrophages than in monocytes 
for cels from al donors we examined, including cels from a leukopack that was shipped 
overnight and processed at least 24 hours after the initial blood draw (Figure 1, Table 2). 
Similar upregulation was previously reported by in primary cels [14] and during PMA-
induced differentiation of myeloid leukemic cel lines [15,18,23] (Table 1). Like miR-
29a, miR-29b is upregulated during monocyte-to-macrophage differentiation. However, 
miR-29b is generaly present at lower copy numbers than miR-29a, and low signal 
intensity precluded a definitive conclusion of differential expression in cels from the 
third donor. Upregulation of miR-29b was also observed in monocyte-to-macrophage 
differentiation of cels from the leukopack. 
 
2.3. Ant-HIV-1 miRs-28-3p, -125b, -150, -223, and -382 
 HIV-1 3' LTR site-specificity of miRs-28-3p, -125b, -150, -223, and -382 was 
demonstrated using reporter/mutation assays as described above [44]. The authors of this 
report ascribed to these miRNAs a role in mediating HIV-1 restriction in resting versus 
activated T-cels [44]. To date, direct interactions of these miRNAs with HIV-1 do not 
appear to have been confirmed by independent researchers; however, anti-HIV efects of 
some of these miRNAs were later reported in monocyte-derived cels [13] or during drug 
treatment of monocyte-derived cels [45,46]. It was reported that the levels of four of five 
of these miRNAs—miRs-28, -150, -223, and -382, as measured by qPCR—fel 
dramaticaly (in some cases by more than ten-fold) during differentiation of monocytes 
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into macrophages [13] and concluded that downregulation of these miRNAs likely 
enables permissivity to HIV-1 replication in macrophages. 
 However, there are several potential complications with this interpretation. First, 
in a response by Swaminathan et al. [47], it was argued that the presented data could not 
support a conclusive statement that the four miRNAs were involved in differential 
susceptibility of monocytes and macrophages to HIV-1 infection, and that non-HIV 
targets of these miRNAs must be considered in any analysis of their role in HIV-1 
restriction. Second, data normalization methods were not described [13]. In two 
subsequent publications by the later group, normalization using a GAPDH assay was 
described in one paper [45] but not in another [46]. Third, since only downmodulation 
was reported, with no miRNAs or other nucleic acid molecules shown to remain constant 
or to increase, it is not clear if the reported declines were associated with monocyte 
differentiation or, rather, with cel death or changes in cel numbers that would have non-
specificaly affected miRNA levels. Indeed, with the exception of miR-223, our results 
have limited agreement with these findings. 
 miR-223. We confirmed downregulation of miR-223 in macrophages, as 
previously reported in primary cels [13,14] and in a cel line model [21]. The magnitude 
of the observed downregulation is also consistent with previous findings. 
 miR-28-3p. A slight decline was observed for miR-28-3p but the fold changes 
were smal (<1.5), and inconsistent data meant that this result was dependent on analysis 
method. Our study thus provides no solid evidence for differential regulation of miR-28-
3p. In future studies, this miRNA could be quantitated in larger groups of samples to 
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determine whether or not there is in fact subtle modulation during monocyte 
differentiation. 
 miR-125b. Signal for miR-125b did not consistently exceed background in our 
arrays. Thus, either miR-125b levels were very low in the monocytes and macrophages 
we examined, or the hybridization platform was insensitive in our hands to miR-125b. 
We note that an increase in miR-125b was previously observed in cels from one of two 
donors [14], and that the closely related miR-125a (100% identical with miR-125b in the 
5' 13 nucleotides) was strongly enriched in macrophages both previously [14] and in our 
results described herein. 
 miR-150. miR-150 was consistently and strongly upregulated in each of our 
experiments, including the leukopack experiment. Previously, upregulation was reported 
in one of two donors [14]. In contrast, miR-150 was reported to be downregulated 
approximately ten-fold in MDM according to Wang et al. [13]. 
 miR-382. The quantitation of miR-382 was not possible in our samples, since the 
fluorescence intensity was below the threshold of detection for miR-382 in al samples 
except those from the leukopack. Although the presence of very low levels of this 
miRNA cannot be ruled out, we emphasize that there does not appear to be strong 
evidence for substantial expression of this miRNA in monocytes or macrophages, much 
less differential regulation. We re-analyzed several published studies as wel as publicly 
available datasets, which either did not reveal the presence of miR-382 in monocytes (or 
monocyte-containing cel populations) [48–50] or reported no differential regulation 
[14,49]. Alantaz et al. found no miR-382 in nine of nine monocyte samples measured in 
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one facility, but they did find low levels in monocytes from two of five donors in a 
separate profiling experiment conducted in a diferent laboratory [51]. 
 Thus, for the five miRNAs that were originaly published as anti-HIV miRNAs in 
CD4+ T-cels [44], our findings and the preponderance of evidence from published studies 
and public datasets support the conclusion that only miR-223 appears to be 
downregulated during differentiation of monocytes into macrophages and thus consonant 
with a straightforward role in the relaxation of HIV-1 restriction during monocytic 
differentiation. miR-150, like the miR-29 family members, is consistently more abundant 
in macrophages than in monocytes. 
2.4. miR-198 
 miR-198-mediated control of Cyclin T1 contributed to restriction of HIV-1 
replication in monocytes, and this control was relaxed with downregulation of miR-198 
in macrophages [14]. Examination and/or re-analysis of several published reports and 
other datasets supports the reported low or negligible macrophage levels of miR-198. Re-
analyzing a qPCR array dataset from a study of HIV-1-infected and uninfected PBMC 
(n = 6 each), we found that after sufficient time in culture to promote monocyte 
differentiation, miR-198 amplified only sporadicaly and inconsistently [52]. Similarly, a 
study of macrophage miRNA populations did not detect miR-198 in macrophages by 
hybridization microaray [53]. We also found no detectable miR-198 in uninfected (n = 
6) or infected (n = 42) thalamus samples from a macaque model of HIV encephalitis 
(brain includes both resident microglia and perivascular macrophages—data not shown). 
 To what extent miR-198 may be differentialy regulated in monocytes remains an 
intriguing question. In addition to the work by Sung and Rice, hybridization aray 
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profiling of monocytes and other leukocytes pinpointed low levels of miR-198 in some 
cel types, including monocytes, with levels varying up to 3.5-fold between different 
donors [51], and low-level miR-198 expression was found at day zero in a study of 
monocyte-to-dendritic cel diferentiation [49]. However, other evidence has not 
supported the presence of miR-198 in monocytes. We did not detect miR-198 in the 
monocytes or macrophages in the work reported here (Table 2b), or in RNA from freshly 
isolated PBMC from controls or HIV-1-infected individuals, as measured by qPCR or by 
NanoString miRNA hybridization microarray [54]. Re-analyzing an Affymetrix 
hybridization array dataset from van Eijsden and Ayoubi [55], we found no appreciable 
expression of miR-198 in any examined blood cel subtype, including monocytes. 
Another dataset, from Agilent arrays performed by Murray and Swaminathan [50], 
included profiles of monocyte miRNAs from eight control and 16 HIV-infected subjects, 
with inconsistent expression of miR-198, which was also not detected in CD14+ 
monocytes from control or morbidly obese individuals (Exiqon array) [48]. Thus, 
although it would appear to be amply confirmed that miR-198 is not present, or is present 
at only very low concentration, in macrophages, there is some evidence that abundance in 
monocytes may be quite variable. Given the importance of miR-198 for Cyclin T1 
regulation in monocytes as established by the Rice laboratory, further work is needed to 
establish the level and variability of miR-198 expression in monocytes and monocyte 
subtypes, the possible dependence of successful quantitation on monocyte isolation 
protocols, and the ability of different profiling platforms to detect and quantitate miR-198 
successfuly. 
2.5. miR-17/92 Cluster 
 72 
 Members of the polycistronic miR-17/92 cluster are transcribed from human 
chromosome 13, and closely related miRNA clusters are found on chromosomes 7 and X 
(Supplementary Table 1b) [56]. These miRNAs are related by sequence as wel as co-
transcription. The chromosome 13 cluster was downmodulated folowing HIV-1 infection 
of Jurkat cels [57]. Furthermore, several members of the cluster were found to suppress 
HIV-1 replication indirectly, through direct regulation of the histone acetyltransferase 
PCAF [57]. At least one member of the cluster—miR-18a—was predicted to interact 
directly with HIV-1 [44], although another group reported different results [57]. 
 Almost every member of the three miR-17/92 clusters was downregulated two- to 
five-fold with monocyte-to-macrophage differentiation: miRs-17, -18a, -19b, -20a, -20b, 
-25, -92a, -93, -106a, -106b, and -363. Previously, in primary cels, miRs-17, -20a, and -
106a were differentialy regulated [12], while downmodulation of miR-19b was reported 
for cels from one of two donors [14]. miR-17 was also the most consistently 
downregulated miRNA in the various reports on PMA-stimulated cel lines (see Table 1). 
2.6. Additional miRNAs — Direct Interactions? 
 HIV-1 target sites have been proposed for a host of miRNAs in addition to those 
discussed above (Supplementary Table 2). Hariharan et al. used multiple targeting 
algorithms to predict HIV-1 target sequences in isolates representing several virus clades 
[37]. Nathans et al., who confirmed the direct miR-29a/HIV interaction, also predicted 
binding sites in the 3' LTR for eight miRNAs not in the miR-29 family [36]. Schopman et 
al., recently performed in silico analysis of interactions for 38 miRNAs that were 
enriched in smal particles (including virions) produced by SupT1 cels transfected with 
HIV-1 provirus [58]. Interestingly, Huang et al., chose for folow-up the five specific 
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miRNAs mentioned above (-28-3p, -125b, -150, -223, and -382) from among no less than 
96 host miRNAs for which they predicted interactions with HIV-1 [44]. It is not clear 
how the five reported miRNAs were chosen, since these miRNAs did not uniformly have 
the strongest predicted target interactions (as ranked by free energy) or the largest 
number of predicted targets. Although the authors stated that 31 miRNAs were 
downregulated by two-fold or greater in activated versus resting CD4+ T-cels, and that 
al five selected miRNAs were depleted, the results of the microarray experiment they 
presented in the supplementary material showed that (1) only three of the five selected 
miRNAs were downregulated by two-fold or more, and (2) miR-382 does not appear to 
have been detected at al (re-analysis of supplementary data from [44]). 
 These observations raise the exciting possibility that additional smal RNA 
regulators of HIV-1 remain to be characterized, including miRNAs that are differentialy 
expressed in monocyte-to-macrophage diferentiation. Several candidates are indicated in 
Table 2 (‘#’). Of particular interest may be those miRNAs that we found to be 
downregulated in macrophages—including miRs-103, -107, and -425. However, 
upregulated miRNAs should not be ignored (see Conclusions). Characterization of 
previously unknown miRNA-HIV-1 interactions may be best guided in future not by 
target prediction algorithms, but instead by target enrichment strategies like that used by 
Althaus and Vongrad et al. [59]. Indeed, these investigators reported capture of at least 21 
host miRNAs using HIV-1 capture probes in primary cel systems, most of which were 
differentialy regulated in our experiments (Table 2).  
 While puldown of host miRNAs could potentialy be explained by factors other 
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than canonical miRNA-target interactions, these results are compeling, and the method 
wil likely continue to be useful for miRNA-virus interaction studies. 
2.7. Additional miRNAs — Indirect Efects 
 Apart from additional members of the miR-17/92 clusters, our results indicate 
differential regulation of more than ten miRNAs that have not been previously associated 
with monocyte-to-macrophage differentiation in primary cells (Table 2, Groups II and 
III) and that do not have previously predicted [60,61] binding sites in HIV-1 sequences. 
Potential indirect effects of these miRNAs on HIV-1 should be considered, as described 
for the miR-17/92 cluster and miR-198, above. Some known indirect effects do not 
appear to factor in the monocyte-macrophage system. A role for miR-27 has been found 
in CD4+ T-cels [38], but we do not find differential expression of miR-27 family 
members here. miR-217 promotes LTR transactivation by inhibiting the SIRT1 
chromatin modifier [62]; however, we did not detect miR-217 in these cels. 
3. Experimental Section 
3.1. Cel Isolation and Culture 
 Total PBMC were isolated from freshly drawn blood from human donors or a 
leukopack (shipped overnight from New York Blood Center) using a Ficol gradient. 
CD14+ monocytes were isolated from total PBMCs using anti-CD14 beads (Dynal) and 
were assessed by flow cytometry (FACSCalibur, BD Biosciences) as >98% pure and 
viable. Total PBMCs were plated at 107 cels per wel in 6-wel plates for macrophage 
differentiation as described previously [29]. Macrophages were diferentiated in culture for 
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7 days in medium containing human serum and M-CSF (R&D), with half re-feeding at 
day 4. 
3.2. RNA Extraction 
 RNA from monocytes and macrophages was extracted using the Trizol Reagent 
(Life Technologies) RNA extraction protocol. RNA quality was assessed by 
spectrophotometry. 
 
3.3. miRNA Microarrays 
 One microgram aliquots of each RNA sample were poly(A) tailed and labeled 
with Alexa fluor dendrimers AF3 or AF5 (fluorescing in the green and red channels, 
respectively), using the NCode Rapid miRNA Labeling Systems (Invitrogen). For each 
donor, two dye-swap array hybridizations were performed with monocyte and 
macrophage RNA with NCode Human miRNA microarrays (V3). The NCode V3 is a 
spoted array on a glass slide. Each probe is a tandem repeat of a sequence corresponding 
to a target. The slide includes probes to over 700 human miRNA targets and additional 
smal RNA sequences reportedly identified by the producer in deep sequencing analyses. 
Three replicates of each probe are printed on each slide. Arrays were maintained at 52 °C 
overnight in Maui mixer stations and covered with Maui chamber slips (SL from 
BioMicro Systems) for hybridization solution recirculation. Slides were then washed for 
15 minutes in each of the folowing solutions, pre-warmed to 55 °C: 2× SSC, 0.2% SDS; 
2× SSC; 0.2× SSC. Slides were scanned with an Axon scanner (3000B) and GenePix Pro 
software [34]. Gpr files were generated, containing the raw data. 
3.4. Analysis 
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 Multiple analysis methods and software tools were employed to assess method-
independence of results, in part as described previously [63]. Data from al fresh blood 
sample experiments was background corected and thresholded and analyzed using 
normalization methods based on both median and lowess smoothing using BRB-
ArrayTools [42]. The limma package from R/Bioconductor [64] was used to conduct an 
analysis of data from the fresh blood samples. Data were normalized with the 
“printiploess” method. Diferent normalization methods produced results that difered 
only slightly from each other, with some changes in rank; results were confirmed by 
generating RG plots for the data pre- and post-normalization: after normalizing, the red 
and green density curves overlapped each other almost entirely. Boxplots of normalized 
data showed similar medians and ranges of values (data not shown). For linear modeling, 
within-array replicates (three per aray) were taken into account with the “guessdups” and 
“duplicateCorrelation” functions. Empirical Bayes was used to moderate the probability 
distribution. Unmoderated and adjusted p-values and the B statistic were calculated (the 
later is presented in Table 2). 
 Analysis of dye-swap experiments for al donors, including the leukopack 
experiment, was also performed with NCode Profiler software [65], with p-values 
assigned by iteration (10,000 bootstraps). Subsequent analysis was restricted to human 
miRNAs, since the array contained probes for many additional known and predicted 
smal RNAs. Four inclusion filters for analysis of individual miRNA data were 
established. First, data were ranked by p-values as provided by NCode Profiler software 
[65], and miRNA replicates with p-values above 0.05 were eliminated. Second, the 
presence of at least two of three possible dye-swap normalized ratios was required, i.e., 
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values above threshold for both spots and both dyes for at least two of three technical 
replicate sets. Third, satisfaction of the second criterion for each of the first two 
biological replicates was required for inclusion. Finaly, an average absolute fold change 
greater than 1.5 in donors I and II was required. Throughout, Microsoft Excel and the 
MultiExperiment Viewer [66,67] provided additional analysis tools. 
 
3.5. Literature and Data Re-Analysis 
 
 Publicly accessible data were downloaded from the Gene Expression Omnibus or 
from other websites as indicated. Re-analyses were conducted in part or in whole as 
described above. 
3.6. Data Accessibility 
 Raw and processed data for the triplicate studies presented here have been 




 A synthesis of our data, re-examination and re-analysis of other datasets, and the 
smal number of verified miRNA-HIV interactions might be taken to suggest that few if 
any miRNAs that are diferentialy regulated during monocyte-to-macrophage 
differentiation are poised to affect HIV-1 replication. Only one miRNA (miR-223) that 
interacts directly with HIV sequences (and relatively weakly: see Supplementary Table 
2), has been consistently found to be reduced in concentration in macrophages compared 
with monocytes. This single downregulation appears to be greatly outweighed by 
upregulation of highly abundant HIV-1-specific miRNAs with low free energies of 
interaction like the miR-29 family and miR-150 (Supplementary Table 2), as wel as a 
lack of evidence for downregulation (or indeed presence) of other previously reported 
anti-HIV miRNAs. 
 Nevertheless, we posit that dismissing macrophage-enriched miRNAs as 
irrelevant for HIV-1 regulation would be a mistake. The notion that the concentration of a 
specific miRNA must necessarily inversely correlate with the abundance of a single 
target transcript (or transcript product) is conceptualy appealing but perhaps 
oversimplistic, particularly when different experimental conditions or cel types are 
compared. Changes that occur during the differentiation of monocytes into 
macrophages—transcriptional, proteomic, morphological—are sufficiently profound that 
they may greatly complicate stand-alone interpretation of before-and-after profiling of 
miRNAs (Figure 2). Since each putative anti-HIV miRNA may have scores or hundreds 
of host mRNA targets, as wel as targets in longer non-coding RNAs, and since the 
strengths of these interactions and the turnover rates of specific transcripts vary [68], the 
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regulatory pressure exerted by a given miRNA on HIV-1 would be best predicted within 
the prevailing transcriptional environment [69]. Thus, enrichment of miR-150 and miR-
29a in macrophages does not necessarily mean that these RNAs have no role in HIV-1 
restriction in monocytes. 
 Furthermore, in addition to the celular balance of targets and specific miRNAs, 
the overal numbers of HIV-1-interacting miRNAs would have to be considered in an 
efective assessment of miRNA/HIV-1 regulation. It is unlikely that we know the 
identities of al miRNAs with regulatory target sites in the HIV-1 genome, or in 
prominent sequence variants. Recal that Huang et al. investigated and validated only five 
miRNAs out of 96 predicted HIV-1 interactors [44], and that only miR-29a has been 
confirmed by multiple laboratories to bind directly to HIV-1. More research is needed to 
confirm previously reported HIV-1 interactors and to identify additional smal RNAs that 
interact with HIV-1. 
 Advances on the miRNA-HIV-1 targeting questions would idealy be 
accompanied by larger miRNA profiling studies of cel diferentiation and activation than 
those that have been conducted to date. Stemming from observations we made while 
conducting the multiple re-analyses presented above, we would like to present several 
considerations to guide future profiling studies in this field. First, biological replicates are 
essential in al profiling work, since each represents a different human and captures 
genetic heterogeneity between individuals. Some studies to date have included only one 
sample per condition, precluding statisticaly based conclusions about the underlying 
biology [70,71]. Second, the technical demands of each profiling system must be taken 
into account [33,72]. For example, dual-channel microarrays are susceptible to artifact 
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because one dye may be brighter than the other, necessitating dye-swap experiments. 
Third, careful data processing and normalization should be performed and described to 
alow replication. Fourth, valid statistical analysis should include multiple comparison 
correction when statistical analysis is reported for large datasets [73]. Finaly, we urge 
authors of future profiling studies to maximize the usefulness and impact of their work by 
depositing MIAME-compliant [19] raw and normalized data with one of the public 
databases, such as the Gene Expression Omnibus (GEO) [74] or ArayExpress [75]. 
 As research proceeds, it wil be important to study how cel isolation and 
differentiation protocols affect miRNA profiles, and to examine—in addition to 
monocytes and macrophages as a whole—the various subpopulations of these cel types 
that have been described [76–78]. On the first point, we note that our cel culture 
conditions and those of the closely related study of Sung and Rice [14] employed M-CSF 
and GM-CSF, respectively, which could account for some diferences between our 
results, while at the same time emphasizing the robustness of the common results. On the 
second point, further miRNA profiling may aid in defining and characterizing cel 
subclasses. In this direction, Graff et al., recently contributed a profiling study on 
differences between untreated MDM and those polarized towards different phenotypes 
(M1, M2a, M2b, and M2c) [79]. miRNAs identified in this report included miRs-125a, -
146a, -155, and -222. Additional profiling studies are needed, along with development of 
tools for functional studies [80], to address the many outstanding questions in this field. 
As more transcriptome and miRNA profile datasets are colected rigorously and made 
available to the community, we can expect new insights into the complex post-
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transcriptional regulatory networks that influence HIV-1 replication in monocytes and 
macrophages. 
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Wang Coley Forrest Chen, Kasashima 
miRNA 
U937 U937 THP-1 HL-60 
down 
miR-17 
x   x 
up 
miR-21 
x   x 
miR-22 x x x  
miR-23a/b x x  x 
miR-24   x x 
miR-26a/b x x  x 
miR-27a/b x   x 
miR-29a x x x  
miR-29b x x x  
miR-132  x x  
miR-146a x  x x 
miR-146b x x x x 
miR-221 x x x x 
miR-222 x x x x 
miR-424 x  x x 
miR-663 x x   
     
Table 1. Commonly reported regulated miRNAs: U937, THP-1, HL-60 diferentiation. 
Results of five studies of PMA-induced U937, THP-1, or HL-60 monocyte diferentiation 
models were compared: Wang et al. [18], Coley et al. [15], Forest et al. [23], and 
Chen et al. [25], and Kasashima et al. [26] (combined). Only miR-17 was reported to be 
downregulated by more than one group, although al but Coley et al. reported 
downregulated miRNAs. Upregulated miRNAs were reported by J. Wang et al. (>30), 
Coley et al. (>60), Forrest et al. (>20), and the Chen and Kasashima studies 
(>10 combined). The 15 miRNAs presented here were found to be upregulated in at least 




Figure 1. Graphic representation of fold changes for selected miRNAs, comparing 
monocytes with monocyte-derived macrophages. Positive values indicate enrichment in 
macrophages over monocytes. Fold changes were calculated for each miRNA from each 
of three donors: I, II, and III, using normalization by median centering for two dye-swap 
array experiments for each donor/sample with averaging of three triplicate measurements 
for each miRNA. Results of a leukopack experiment are also shown. ‘A’ and ‘B’ are 
provided for the sake of comparison: the results of hybridization array analysis performed 
and reported previously by Sung and Rice and calculated from data obtained from the 
Rice lab website [41]. Gray indicates that the coresponding miRNA was not detected or 
not differentialy regulated in the respective arrays. See Table 2 for exact fold change 
calculations, statistics, and results of alternative analysis. MIAME-compliant raw and 
processed data from the triplicate fresh blood draws are available from GEO as 
GSE39905; leukopack data are available upon request.
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(a) 




Group miRNA B 




I miR-15b 0.37 −2.45 −2.89 −2.80 −3.95 −3.72 −3.05  −6.03 −2.61  
 miR-16 0.82 −2.52 −3.11 −2.61 −3.67 −2.04 −1.72  −1.93 −1.79  
 miR-19b  −2.42 −2.82 −2.58 −3.13 −1.80 −2.11 2.46 −4.16 2.25  
 miR-26a  −1.95 −2.39 −2.82 −3.92 −2.81 −2.38  −3.72 −2.52 * 
Table 2. Cont. 




Group miRNA B 




 miR-26b  −2.09 −2.56 −3.27 −4.40 −2.64 −2.02  −5.41 −2.73 * 
 miR-29a 0.78 2.25 1.79 2.11 1.48 1.51 1.73 5.34 2.92 1.58  
 miR-30b  −3.08 −3.72 −2.78 −3.61 −1.29   −2.54 −1.60  
 miR-30c 0.55 −2.46 −2.91 −2.97 −3.77 −1.55   −1.75 −1.67  
 miR-30d  −2.35 −2.74 −1.95 −2.65 −1.67  2.14 −2.07 −1.59  
 miR-99b 3.07 3.73 2.63 4.16 2.51  1.94 3.29 33.77 61.46  





−3.26 −3.78 −3.48 −4.42    −5.08 −2.07  





6.65 5.59 5.50 6.10 3.05 3.90 6.06 8.91 30.89 # 
 miR-150 1.96 5.99 4.12 14.29 8.69 2.27 2.50 5.49 −2.66 1.99  
 miR-155 4.54 5.46 4.33 4.86 3.38 2.82 3.11 6.25 8.94 3.00  
 miR-191  −1.33 −1.66 −1.77 −2.46 −2.56 −2.14 2.79 −1.41 −1.89 * 
 miR-221 1.97 3.02 2.43 2.28 1.63 1.84 2.06 5.37 6.36 2.81 # 
 miR-222 1.32 4.36 3.47 2.37 1.63   5.48 7.26 3.22 # 





7.01 5.40 6.16 4.23 1.62 1.80 7.39 8.40 3.27  
I let-7b  −1.96 −2.42 −1.54 −2.17 −1.49  1.97   # 
 let-7c  −1.62 −1.97 −1.65 −2.30 −1.60  2.28   # 
 miR-15a  −2.52 −3.07 −2.68 −3.65 −2.84 −2.19    # 
 miR-17 0.91 −3.71 −4.30 −3.56 −4.50 −2.72 −2.01     
 miR-18a  −2.15 −2.25 −1.49 −2.30  −1.63    # 
 miR-20a 2.61 −3.36 −4.01 −3.89 −5.09 −3.20 −2.52 −1.67    
 miR-20b 0.01 −2.97 −3.45 −1.36 −2.43  −1.57    # 
 miR-25  −2.40 −2.84 −2.38 −3.22 −2.67 −2.18     
 miR-29b 0.89 2.37 1.81 2.83 1.79   2.37    
 miR-34a 4.19 10.66 6.97 7.39 6.16 2.02 2.53 5.15   * # 




















−1.97 −2.31 −1.70 −2.32 −1.18  3.38   * 
 miR-210 1.32 2.89 2.71 4.39 3.88 1.31 1.54 2.14   * # 
 miR-425  −2.03 −2.39 −1.85 −2.44 −1.86 −1.78 1.62   # 
 miR-484  −2.26 −2.71 −2.79 −3.55 −2.23 −1.85     
II miR-1 4.90 11.14 7.19 4.98 4.90       
 miR-10b  −1.91 −2.02 −1.46 −1.74       
 miR-30e  −2.81 −2.82 −1.39 −2.62       
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−2.21 −2.41 −1.61 −2.13       
 miR-363 1.62 −2.15 −2.89 −1.50 −2.76       
(b) 





et al. miRNA 
MC DS MC DS MC DS DS A B  
miR-28-
3p 
nc −1.63 nc −1.65 nc nc nc nr nr ~−2 
miR-
125b 
bb bb bb bb bb bb bb nr 1.83 nr 
miR-
125a-5p 
6.65 5.59 5.50 6.10 3.05 3.90 6.06 8.91 30.89 nr 
miR-150 6.00 4.12 14.29 8.69 2.27 2.50 5.49 −2.66 1.99 ~−10 
miR-223 −4.23 −5.31 −6.95 −9.88 −5.15 −4.18 −1.72 −5.96 −5.61 ~−10 
miR-198 bb bb bb bb bb bb bb −8.87 −59.18 nr 
miR-382 bb bb bb bb bb bb −1.66 nr nr ~−10 
 
Table 2. Differential regulation of miRNAs in monocyte-to-macrophage diferentiation. 
(a) miRNA expression profiles of day zero monocytes and day 7 macrophages were 
assessed by hybridization microarray in dye-swap experiments with three technical spot 
replicates per array. Hybridization arrays for Donor I and I arays were processed 
together in one batch, while Donor II samples were hybridized several months later to 
assess reproducibility of results. Also included are results obtained with cels from a 
leukopack, which was shipped overnight before cel processing (with at least 24 hours 
between leukapheresis and cel/RNA isolation). Datasets for donors I and I were 
analyzed folowing print-tip loess normalization by fiting linear models to the data with 
limma (R/Bioconductor) and moderating with empirical Bayes smoothing. The ‘B’ 
statistic is the empirical Bayes log odds of diferential expression, with positive values 
considered to be statisticaly significant (corresponding approximately to moderated p < 
0.01). Datasets for donors I, I, and II were also analyzed with different methods, with 
the results displayed under “MC” (high background cutoff, median array centering, using 
BRBArray-Tools software [42]) or “DS” (Dye Swap, using NCode Profiler software 
[43]). Calculated fold change values indicate up- (positive, black) or downregulation 
(negative, red) in macrophages as compared with progenitor monocytes from the same 
donor. miRNAs included in group I displayed consistent regulation for donors I and II, as 
assessed by both indicated normalization/analysis methods, with an average FC of 1.5 or 
greater; plus confirmation in the original Sung and Rice dataset. Italics indicate 
inconsistent regulation in the two Sung and Rice donors. Group II contains miRNAs that 
were not reported by Sung and Rice but were confirmed in our experiments for either or 
both of the third donor or the leukopack. Group II members have evidence for 
differential regulation only in the datasets for donors I and II and have not been 
confirmed independently. Bold indicates miRNA with reported direct or indirect roles in 
regulation of HIV-1. Purple values highlight regulation opposite that observed for the 
majority of datasets analyzed. The “New Interaction” column indicates candidates for 
novel HIV-1 interactions: miRNAs with published predicted binding sites in the HIV-1 
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genome that have not yet been confirmed experimentaly (‘#’) or miRNAs that were 
puled down with HIV-1 enrichment probes (‘*’) by Althaus and Vongrad et al. (b) Fold 
change for miRNAs with previously reported roles in monocyte-to-macrophage 
differences in restriction of HIV-1 replication. This table includes data duplicated from 
‘a’ as wel as results that did not meet the data filters for ‘a’. Data are presented for 
miRNAs reported by Wang et al. [13] or by Sung and Rice [14]. nc = no change, i.e., 
<1.5 fold change and/or no significant difference in technical replicate groups; nr = not 
reported; bb = below background. Approximate downregulation (final column) has been 






Figure 2. miRNA-mediated regulation depends on factors in addition to miRNA copy 
number. A hypothetical host miRNA (red) and the RISC machinery binding to the HIV-1 
transcript in a monocyte but not in a macrophage. With differentiation of the monocyte, 
the miRNA is upregulated two-fold, but a host target transcript (blue) with a high-affinity 
target site for the miRNA is also produced, acting as a “sponge” for most of the miRNA 
copies. Thus, alongside miRNA copy number, the copy numbers and binding affinities of 
both the original target of interest and al possible alternative targets are determinants of 
the extent of miRNA-mediated regulation. RISC component availability, other targeting 
miRNAs, RNA binding cofactors, and subcelular localization of interaction partners may 
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Background: Host cel microRNAs (miRNAs) have been shown to regulate the 
expression of both celular and viral RNAs, in particular impacting both Hepatitis C 
Virus (HCV) and Human Immunodeficiency Virus (HIV). To investigate the role of 
miRNAs in regulating replication of the simian immunodeficiency virus (SIV) in 
macrophage lineage cels, we used primary macrophages to study targeting of SIV RNA 
by miRNAs. We examined whether specific host miRNAs directly target SIV RNA early 
in infection and might be induced via Type I interferon pathways. 
Results: miRNA target prediction programs identified miRNA binding sites within SIV 
RNA. Predicted binding sites for miRs-29a, -29b, -9 and -146a were identified in the 
SIV Nef/U3 and R regions, and al four miRNAs decreased virus production and viral 
RNA expression in primary macrophages. To determine whether levels of these miRNAs 
were affected by SIV infection, IFNβ or TNFα treatments, miRNA RT-qPCR assays 
measured miRNA levels after infection or treatment of macrophages. SIV RNA 
expression as wel as virus production was downregulated by direct targeting of the SIV 
Nef/U3 and R regions by four miRNAs. miRs-29a, -29b, -9 and -146a were induced in 
primary macrophages after SIV infection. Each of these miRNAs was regulated by innate 
immune signaling through TNFα and/or the Type I IFN, IFNβ. 
Conclusions: The efects on miRNAs caused by HIV/SIV infection are ilustrated by 
changes in their celular expression throughout the course of disease, and in different 
patient populations. Our data demonstrate that levels of primary transcripts and mature 
miRs-29a, -29b, -9 and -146a are modulated by SIV infection. We show that the SIV 3’ 
UTR contains functional miRNA response elements for al four miRNAs. Notably, these 
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miRNAs regulate virus production and viral RNA levels in macrophages, the primary 
cels infected in the CNS that drive inflammation leading to HIV-associated 
neurocognitive disorders. This report may aid in identification miRNAs that target viral 
RNAs and HIV/SIV specificaly, as wel as in identification of miRNAs that may be 
targets of new therapies to treat HIV. 





 Approximately 34 milion people worldwide are currently infected with HIV 
according to the World Health Organization (htp:/www.who.int/features/qa/71/en/index.html). 
As a result of the development of Highly Active Antiretroviral Therapy (HAART), 
infected individuals are living longer, healthier lives than just two decades ago. Despite 
this success, patients living with HIV often suffer from complications associated with 
long-term infection such as cardiac and neurological disorders, in addition to side effects 
from antiretroviral drugs [1, 2]. Along with HAART treatment, recently there has been 
research targeted at HIV eradication focused on therapeutic vaccine development [3], 
purging the latent reservoirs that harbor virus [4], and reducing the expression of the 
CCR5 co-receptors [5], cel-surface proteins, used by HIV for entry into cels. To this 
end, a beter understanding of HIV-host interactions is needed.  
 The Type I IFN response is a major host defense against virus infection [6, 7]. 
HIV infection initiates a cascade of cytokine induction and innate immune signaling. In 
our SIV macaque model of HIV central nervous system (CNS) disease, analysis of 
plasma, cerebrospinal fluid, basal ganglia and parietal cortex shows distinct diferences in 
innate immune responses between the periphery and the CNS. This is exhibited by the 
presence of viral RNA accompanied by induction of IFNβ and IFNβ-inducible MxA in 
the CNS as early as 4 days after infection [8]. CD4+ T cels are the main cels in the 
periphery that become infected, in contrast to the central nervous system (CNS), where 
CD14+ macrophages are the predominant productively infected cels [9-15]. Previous 
studies have demonstrated that circulating cels from the monocyte/macrophage lineage 
become infected and trafic to the brain where they induce cytokine signaling and also 
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infect other macrophage lineage cels and astrocytes [6, 16]. Many cytokines, including 
IFNβ, are produced by virus-infected or virus-exposed cels. Soluble IFNβ produced by 
infected cels binds to uninfected cels to signal through the Type I IFN receptor, 
activating over 100 interferon-stimulated genes as wel as antiviral proteins such as MxA 
[17]. Thus, the signal is amplified and a robust antiviral response is activated to prevent 
the spread of infection. Celular restriction factors are another host defense against HIV 
infection. These include, but are not limited to, TRIM5α [18, 19], APOBEC3G [20, 21], 
SAMHD1 [22, 23] and microRNAs (miRNAs) [24, 25].  
 miRNAs are smal regulatory molecules that fine-tune levels of target mRNAs in 
the cel through binding to miRNA response elements (MREs) in target mRNAs. Binding 
results in post-transcriptional repression caused by target mRNA degradation, 
translational inhibition and/or sequestration [26]. Each miRNA may have hundreds of 
predicted target mRNAs, resulting in regulation of expression for close to 60% of human 
mRNAs [27]. miRNAs regulate human physiology at the level of cel cycle and 
differentiation [28] and innate immune signaling and antiviral mechanisms [29-32], as 
wel as yet to be identified genes and pathways. Their actions extend into roles in 
pathogenesis of several viruses including Hepatitis C [30, 33], influenza [34, 35], herpes 
viruses [36, 37] and HIV. 
  miRNAs influence several stages of HIV-1 infection. Humans infected with HIV-
1 have alterations in miRNA profiles [38] with differences in distinct miRNA populations 
in patients with varying levels of CD4+ T cel count/plasma HIV RNA copies [39] and 
elite suppressors [40-43], indicating involvement of miRNAs in response to virus 
infection. HIV modulates levels of several miRNAs at various time points after infection 
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[44, 45] and is also regulated by miRNAs in multiple ways [46]. Specific miRNAs target 
cytokines important in the immune response [47], as wel as transcription factors, such as 
Cyclin T1 [48], which are necessary for transcription of viral genes. Some or al of 
miRNAs miRs-28, -125b, -150, -223 and -382 are reportedly involved in differential 
susceptibility of active and resting CD4+ T cels [49, 50] and monocytes and 
macrophages [51, 52] to HIV infection. Multiple reports suggest direct targeting of HIV-
1 by host miRNAs [24, 44, 53-56]. Hariharan et al., used in silico analysis to identify 
target sites for host miRNAs in HIV-1 vpr (miR-149), vif (miR-324-5p), vpu (miR-378) 
and nef-LTR (miRs-29a and -29b) [53]. A folow-up study by the same group 
demonstrated miR-29a regulation of Nef expression and HIV-1 replication, and 
suggested that this was due to miRNA targeting the HIV-1 Nef transcript [24]. The miR-
29 family was also reported to inhibit replication of HIV-1, demonstrating that the RNA-
induced Silencing Complex (RISC) protein, Ago2, and P body protein, RCK/p54, 
directly interact with viral RNA in a miR-29a-dependent manner [54]. Nathans, et al. also 
showed that miR-29a binds the same MRE in HIV-1 as predicted by Hariharan et al [53], 
and this site is conserved across HIV-1 subsets [54]. Sun et al identified MREs for 
several miRNAs within HIV-1 and reported downregulation of miRs-21, 155, -29a, -29b 
and -29c, and an upregulation of miR-223 in response to HIV-1 infection in CD4+ T cels 
[55]. This group also reported only weak repression of a pNL4-3-Luc reporter by miRs-
29a, -29b and -223, hypothesizing that this was due to a hairpin in this region of HIV-1 
RNA sequence that interfered with RISC/miRNA binding [55]. In contrast to Sun et al, 
Schopman et al found induction of miR-29a in several cel types in response to HIV-1 
infection [44]. This difference may be due to time after infection when miRNA levels 
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were measured or the specific cels that were used for the studies. Finaly, Houzet et al 
used anti-HIV-1 miR-326 as an example that sequence complementarity between a 
miRNA and its target mRNA correlates with inhibited expression of that target mRNA 
[56]. Together, these reports demonstrate modulation in levels of at least 13 human 
miRNAs during HIV-1 infection in various cel types. Two of these miRNAs (miRs-29a 
and -29b) have been validated by more than one study to have an effect on, or to directly 
target HIV-1 RNA transcripts [24, 53-55]. 
 We have developed a rapid and consistent SIV macaque model of HIV/AIDS and 
CNS disease in order to study the celular and viral molecular events and pathogenesis 
during acute, asymptomatic and AIDS stage of disease [6-9, 57]. We have shown both in 
vivo and in vitro that TNFα and IFNβ are induced during acute infection in SIV-infected 
macaques [7, 8], and both cytokines regulate several miRNAs [30, 32, 58]. We 
demonstrate here that TNFα and IFNβ induce specific miRNAs at very early time points 
after SIV infection. SIV infection and cytokine stimulation of primary macrophages were 
used to dissect the mechanisms of miRNA induction, innate immune signaling and 
control of virus infection. We evaluated these miRNAs in regard to their effects on virus 
replication and mRNA levels, ability to target viral RNA sequences and modulation by 
innate immune signaling pathways. We provide evidence that the four miRNAs, miR-
29a, -29b, -9 and -146a, are induced in macrophages during innate immune signaling and 




Predicted miRNA recognition elements (MREs) in SIV 3’ UTR 
 miRNA target prediction programs [59, 60] were used to identify potential 
miRNA binding sites within the 3’ untranslated region (UTR) of SIV 17E-Fr (Figure 1, 
Table 1). Many miRNAs were identified that have predicted MREs (miRNA response 
elements) in the SIV RNA 3’ UTR, and we focus here on miRs-29a, -29b, -9 and -146a, 
(Figure 1A, 1B). Al four miRNAs contain promoter binding sites for transcription 
factors induced during innate immune signaling. miRs-29a and -29b are predicted to 
contain two ISRE (STAT1/STAT2 heterodimer induced by Type I IFN signaling) GAS 
(STAT1 homodimer activated by IFNγ signaling) binding sites in the promoter [61] and 
are induced in response to IFNα/β and IFNγ . The miR-9 promoter contains an NF-κB 
binding site and is induced by TNFα in an NF-κB-dependent manner [58]. The miR-146a 
promoter contains binding sites for, and is regulated by, PU.1 and C/EBPα [62], 
transcription factors induced by innate immune signaling. In addition, the ability of miRs-
29a and -29b to target HIV-1 transcripts has been supported by multiple studies [24, 53-
55]. The transcriptional activation of these miRNAs, in addition to the predicted binding 
sites in the SIV RNA sequence, suggests miRs-29a, -29b, -9 and -146a may be induced 
during the innate immune response and inhibit viral replication. 
 
Effects of miRs-29a, -29b, -9 and -146a on SIV production in primary macrophages 
 To determine if the miRNAs with predicted binding sites in the UTR of SIV have 
an effect on virus production, macaque macrophages were transfected or not with each of 
the miRNAs and infected with SIV twenty-four hours after transfection. Levels of virus 
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released from cels were measured at 24, 48 and 72 hours post-infection (p.i.). At 24 
hours p.i., miR-29a, -29b, -9 and -146a reduced virus production from ~250 pg/ml of p27 
protein to below the limit of detection (~60 pg/ml) (Figure 2). There was a statisticaly 
significant decrease in virus production at 48 hours post-infection by miRs-29a and -29b. 
miR-9 continued to reduce p27 levels to below the limit of detection and miR-146a 
reduced p27 levels to below the limit of detection in cels from one experiment. Virus 
levels were decreased ~4-fold by miR-29a, ~15-fold by miR-29b and ~8-fold by miR-
146a (Figure 2). A statisticaly significant decrease in virus production was maintained 
by al four miRNAs through 72 hours post-infection (Figure 2). 
 
miRNA-mediated reduction of ful-length and spliced SIV RNA 
 To investigate whether these miRNAs exert anti-SIV effects through transcript 
degradation or translation inhibition, total celular RNA was isolated from the same cels 
used in Figure 2. Ful-length and multiply-spliced (tat/rev RNA) viral RNA levels were 
measured by RT-qPCR. Al four miRNAs significantly decreased the levels of ful-length 
(Figure 3A) as wel as multiply-spliced (Figure 3B) SIV RNA. Ful length and spliced 
RNA levels were most significantly reduced at 24 hours after infection when viral RNA 
abundance is lowest (Figure 3A and 3B, left panels). Experiments were also performed 
using 25 nM of miR-29b and the same reduction in SIV RNA levels was observed using 
this 4-fold lower miRNA concentration (data not shown). 
 We hypothesized that miRNA-specific antisense oligonucleotides (antagonists) 
that decrease the levels of available miRNAs would lead to an increase in viral RNA. 
Antagonists were transfected into macaque macrophages, and cel lysates were colected 
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at 48 hours post-infection. We found that miRNA antagonists for miRs-29a, -29b and -
146a significantly increased levels of SIV RNA when compared to SIV-infected 
untreated cels (Figure 3C). Inhibition of miR-9 did not increase viral RNA levels. This 
was presumably due to the fact that this miRNA is approximately 1000-fold less 
abundant than miRs-29a and -146a (data not shown), and inhibition by low copy number 
miRNAs may be inefficient [63, 64]. 
 
Effects of miRs-29a, -29b, -9 and -146a on expression of a luciferase reporter 
 After identifying predicted miRNA binding sites in the SIV 3’ UTR, a luciferase 
assay was performed to examine the effects of the four miRNAs on expression of 
luciferase from a plasmid containing the predicted sites. Transfection of 293T cels was 
done with a luciferase reporter plasmid alone, or a plasmid with genomic regions 
containing the SIV 3’ UTR. Luciferase expression was measured in the absence and 
presence of miRs-29a, -29b, -9 and -146a. Addition of each miRNA resulted in a dose-
dependent inhibition of reporter gene expression (Figure 4A). Transfection with two 
different scrambled mimics had no effect on expression of the reporter gene (Figure 4A). 
 
Direct Targeting of MREs in the SIV 3’ UTR 
 To determine whether the predicted SIV 3’ UTR MREs were bound by the 
predicted targeting miRNAs, we transfected into HeLa cels biotinylated 50-nucleotide 
RNA oligonucleotide molecules (oligos) that corresponded to wild-type (WT) or mutated 
(mt) MRE seed-binding SIV U3-R regions (Figure 4B). We calculated the diference in 
the percent of each miRNA precipitated by WT and mt oligos. Cels were lysed, and the 
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biotinylated oligonucleotides were selected with strepavidin. Recovered miRNA was 
quantitated by RT-qPCR. The two predicted SIV 3’UTR seed binding sites for miR-29 
family members were included in two oligos corresponding to nucleotides (nts) 10030-
10070 and 10063-10112 of the SIV RNA. The one predicted binding site for miR-9 was 
included in the oligo coresponding to nts 9740-9789 of the SIV RNA. The two predicted 
sites for miR-146a were included in two oligos coresponding to nts 9680-9729 and 
10000-10049 of the SIV RNA (Figure 4B). miRs-29a and -29b bound to the site 
contained within nts 10063-10112 of the SIV genome, however, neither miR-29a nor 
miR-29b bound to the predicted site within nts 10039-10070 (Figure 4C). miR-9 bound to 
its predicted site contained within nts 9740-9789 (Figure 4C). miR-146a bound to the 
predicted site contained within nts 9680-9729, but did not bind to the predicted site 
contained within nts 10000-10049 (Figure 4C). These results demonstrate that there are 
functional binding sites for miRs-29a, -29b, -9 and -146a within the SIV 3’ UTR.  
 
Upregulation of mature anti-SIV miRNAs during SIV infection of primary 
macrophages 
 To examine whether SIV infection affects the levels of miRs-29a, -29b, -9 and -
146a, each of these miRNAs was measured in primary macaque macrophages after SIV 
infection and compared with miRNA levels in uninfected time-point controls. Levels of 
al 4 miRNAs increased during infection (Figure 5). Primary macrophages were infected 
with SIV, and RNA was isolated at 2, 4, 8, 12, 24 and 48 hours post-infection. miR-29a 
and -29b levels increased together at 12 hours and by 50% and 60%, respectively, at the 
48-hour time point (Figure 5A and B). Levels of miR-9 increased approximately 50-85% 
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4 hours after infection in three out of four animals (Figure 5C). There was also an 
increase in miR-146a levels at 12 and 24 hours after infection, with the largest average 
increase being 50% at 24 hours (Figure 5D). These data demonstrate an induction of 
mature miRNA levels during early stages of SIV infection and suggest that an increase in 
the levels of these miRNAs may contribute to the decrease in SIV replication and viral 
RNA levels that we have shown here. 
 
IFNβ-mediated upregulation of precursor and mature anti-SIV mRNAs 
 The increase in levels of miRs-29a, -29b, -9 and -146 (Figure 5) in response to 
SIV infection is unlikely to be caused directly by the virus, since the only viral proteins in 
the cels at this time are from the virion. IFNβ has been shown to modulate expression of 
miRNAs in our laboratory and by others [30, 32], specificaly miRs-29a and -29b [61]. 
We examined the effects of IFNβ treatment of cels on the expression levels of al four 
miRNAs. Human macrophages were used so that both the mature and pri-miRNAs could 
be measured (pri-miRNA assays have not been developed for macaque sequence). 
Macrophages were treated with IFNβ, and RNA was extracted at 4, 8, 12 and 24 hours 
after treatment. IFNβ caused a modest but consistent increase in the levels of miRs-29a 
and -29b at early time points, with no discernable difference observed for miRs-9 and -
146a (Figure 6A-D). miR-29a was increased significantly at eight hours by 25% and 
miR-29b was increased similarly after stimulation with IFNβ (Figure 6A, 6B). Levels of 
miR-146a showed a similar trend at 8 hours (Figure 6D). This data shows that IFNβ 
induction early in infection leads to an increase in levels of miR-29a and -29b in primary 
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human macrophages. IFNβ treatment produces similar results in primary macaque 
macrophages (Supplemental Figure 1A-D). 
 The increase in levels of mature miRNAs can be due to a decrease in miRNA 
turnover, an increase in transcription of precursor miRNAs (pri-miRNAs), or an increase 
in mature miRNA processing. To address at what level these miRNAs were being 
increased, pri-miRNA levels were measured in primary human macrophages at 2, 4, 8, 12 
and 24 hours after IFNβ treatment (Figure 6E-H). Expression of pri-miRs-29a and -29b 
was significantly increased ~2-fold at 2, 4 and 8 hours after IFNβ treatment (Figure 6E, 
6F). Coordinated regulation of these two miRNAs was expected, as they are part of the 
same transcript. Expression of miR-146a was increased 44% at 8 hours after treatment 
(Figure 6H). Transcription of miR-9 was significantly decreased at al time points (Figure 
6G), explaining the lack of induction of the mature miRNA by IFNβ. An increase in the 
pri-miRNA indicates IFNβ stimulation caused an upregulation of the transcriptional 
activation of the three miRNA.  
 The canonical response to IFNβ was confirmed by measuring the levels of the 
interferon-stimulated gene, mxa. Both SIV infection and IFNβ stimulation significantly 
increased mxa expression (Supplemental Figure 2A, 2B), and IFNβ also reduced viral 
RNA levels (Supplemental Figure 2C). These results demonstrate canonical signaling of 
pathways downstream of IFNβ in our primary macrophage system. 
 
TNFα signaling drives expression of IFNβ and anti-SIV miRNAs 
 In primary macrophages, IFNβ stimulation modulates levels of pri- and mature 
miRs-29a and 29b, and pri-miR-146a (Figure 6A-H). Like IFNβ, TNFα is induced during 
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the acute phase of SIV infection as part of the innate immune response [8], and TNFα has 
been shown to increase expression of IFNβ and interferon-stimulated genes [65]. TNFα 
stimulation of primary macrophages resulted in an increase in the IFNβ-stimulated gene, 
mxa (Figure S3), demonstrating regulation of this pathway by TNFα. To test the efect of 
TNFα stimulation on miRNA levels, primary macrophages were treated or not with 
TNFα and cels harvested at 2, 4, 8, 12 and 24 hours after treatment. TNFα stimulation 
resulted in an increase in miR-29a and -29b levels by an average of 30% and 35%, 
respectively, at 12 hours (Figure 7A, B). miR-9 levels increased significantly at 2 and 24 
hours after treatment by 40% and 90%, respectively (Figure 7C). Levels of miR-146a 
increased maximaly by 55% at 24 hours (Figure 7D). Macaque macrophages responded 
similarly to stimulation with TNFα (Figure S4A-D). 
 TNFα stimulation also induced transcriptional expression of al four miRNAs 
(Figure 8E-H). pri-miR-29a expression increased by ~45% 2 hours after treatment, with a 
maximum increase of 57% 4 hours after treatment (Figure 7E). Similarly, pri-miR-29b 
expression increased maximaly 2 hours after treatment by 55% and remained elevated by 
~40% 4 hours (Figure 7F). There was a dramatic 10-fold increase of pri-miR-9 2 hours 
after treatment with TNFα. This increase was maintained at 5-fold 4 hours, and 2-fold 
through the 12 hour time point (Figure 7G). pri-miR-146a expression increased by 2-fold 
2 and 4 hours after treatment. An approximate 50% increase was maintained through the 




 The identification of miRNAs as regulators of gene expression has dramaticaly 
changed the understanding of post-transcriptional regulation of celular and viral genes. A 
number of viruses encode miRNAs in their genome that regulated celular genes required 
for replication [66]. We have previously shown that miRNAs in plasma of SIV-infected 
macaques provide a signature of infection and progression to CNS disease, demonstrating 
that SIV infection afects miRNA expression in vivo [67]. In this study, we demonstrate 
for the first time that four miRNAs directly bind to the U3 region of the SIV RNA. 
Further, al four miRNAs, miR-29a, -29b, -9 and -146a, controled SIV virus production 
and replication by decreasing SIV ful length and spliced tat/rev RNAs in infected 
primary macrophages. In addition we provide evidence that these four miRNAs are 
transcriptionaly regulated by the innate immune response, specificaly, TNFα and Type I 
IFN. We have shown previously that virus replication in macrophages increases both of 
these cytokines and thus, it appears that these miRNAs are part of the innate antiviral 
immune response to SIV. 
 The protein products of spliced rev and tat transcripts are critical early in 
infection for progression to later stage and productive infection. The 3’ UTR of SIV 
contains MREs for al four miRNAs, miRs-29a, -29b, -9 and -146a. Al SIV RNAs share 
the same 3’ UTR sequence and therefore, these four miRNAs have the capability to target 
al ful-length and spliced viral transcripts for degradation. In order to have a significant 
impact on virus infection and the propagation of virus, one would hypothesize that 
miRNAs would target the early multiply-spliced genes, preventing the progression of 
virus replication to the productive stage. In addition, we hypothesized that the levels of 
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the miRNAs would be high in the cel or would increase within hours folowing infection 
in a cel or be upregulated in response to early cytokines in bystander cels, preventing 
virus spread to other cels. Levels of the anti-SIV miRNAs studied here increased as early 
as 4 hours post-infection, and miRs-29a, -29b and -146a were significantly induced by 24 
and 48 hours after infection, respectively. From these results, we see that viral infection 
in macrophages upregulates miRNAs that regulate the virus. 
 It has been shown for virus infections, including HIV and SIV, that infection of 
cels, particularly macrophages, leads to the induction of innate immune responses, Type 
I IFN and TNFα [8, 17]. To determine whether the increased levels of the four miRNAs 
that reduce virus infection were induced by the celular response to infection, we used 
INFβ and TNFα to examine the induction of mature as wel as pri-miRNAs. INFβ and/or 
TNFα, two cytokines that are made in response to SIV infection in macrophages 
increased the four miRNAs. INFβ increased miRs-29a and -29b as early as 2 hours after 
treatment. TNFα, in contrast increased levels of miRs-29a, -29b and -146a at 12 hours 
suggesting that its effect was due to stimulation of Type I IFN. TNFα may have a direct 
effect on miR-9 since the miRNA was significantly increased at 2 hours and appears not 
to be modulated through the Type I IFN response. Overal, levels of the mature form of 
these miRNAs increased approximately 50% over control. 
While these increases were modest, we found them consistently, and it is 
important to remember that viral infection drasticaly alters the pre-existing miRNA-
target network in many ways. Upon infection, host miRNAs that may have multiple host 
targets are provided with many copies of a new, viral target. The abundance of celular 
transcript targets may also be modulated. Since the number of targets of a specific 
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miRNA and the affinity of the targeting miRNA for each target together influence the 
magnitude of regulation along with the abundance of the miRNA itself, large fold 
changes or indeed any modulation of targeting miRNA are not necessarily prerequisites 
for regulation of an evolutionarily novel target. Further investigations of the entire 
network are needed to establish the necessary stoichiometries for effective regulation. We 
would also note that this miRNA/target network is even more complicated in vivo, as 
levels of the characterized miRNAs may be altered in cel types other than macrophages. 
These miRNAs may traffic between cels [68] and may be recycled within a given cel 
[69], thereby enhancing their efects. 
 A second important finding is that innate immune responses induced these 
miRNAs at the transcriptional level. During this early time after infection, SIV spliced 
RNA encoding Rev and Tat are produced, and this is likely the time when miRNA levels 
are most efficiently targeting viral transcripts to reduce virus replication. Expression of 
each miRNA transcript is controled by specific transcription factors. The promoters of 
miRs-29a, -29b, -9 and -146a al contain one or more binding sites for NF-κB [58, 70, 
71], a transcription factor induced by innate immune signaling. These reports show that 
miRs-9 and -146a are induced by TNFα and induction of miR-146a is dependent on the 
three NF-κB binding sites found in its promoter. In cancer cels, TLR signaling and NF-
κB activation were shown to suppress expression of miRs-29a and -29b [70], but the 
promoter for these two miRNAs contains binding sites for several other transcription 
factors related to innate immune signaling.  
 While miRs-29a, -29b, -9 and -146a did not evolve to target SIV, they reduced 
virus production via direct interaction with specific sequences in the 3' UTR of SIV 
 117 
RNA. In addition, these and other miRNAs may modulate virus infection directly as wel 
as indirectly. For example, miR-29a has been shown to target IFNγ [72]. A report by 
Chiang et al, demonstrates direct binding of Cyclin T1 by miR-29b and [73], a 
transcription factor necessary for replication of HIV-1. miR-9 is induced by TLR 
signaling and NF-κB activation and regulates expression of the NF-κB p50 subunit [58, 
74]. miRNA-146a is a negative regulator of innate immunity and overexpression results 
in downregulation of Type I IFN in PBMCs due to targets within IRAK1 and TRAF6 
[71, 75-78]. miR-146a was also reported to target and inhibit expression of CXCR4 [79], 
a cel surface receptor used by HIV-1 and certain strains of SIV. miRNAs are 
differentialy expressed at various times in different tissues. Furthermore, individual 
miRNAs may have different factors controling maturation as wel as rates of 
degradation. More investigation is needed to elucidate the connections between 
IFNβ/TNFα signaling and our observed modulation of transcription of these miRNAs. 
What is becoming clear is that this miRNA response reflects another downstream 
antiviral innate immune effector.   
 Several lines of evidence suggest that miRNAs may be useful as therapeutic 
inhibitors of HIV-1 infection. These data include: 1) a relationship between differences in 
miRNA profiles and cel type susceptibility to HIV-1 infection [49-52]; 2) dysregulation 
of miRNAs during HIV-1 infection [39] and 3) direct miRNA targeting of HIV-1 RNA 
sequences [54-56]. These reports show the potential for miRNAs to be given 
therapeuticaly as potent inhibitors of HIV-1 infection. The main obstacle is delivery of 
these molecules to a desired tissue or cel population. Several groups have reported 
nanoparticle delivery of antiretrovirals and siRNAs in HIV-infected cels in vitro as wel 
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as in mouse models of neuroAIDS [80]. These methods appear promising for delivery to 
specific cel and tissue types, as wel as only to cels that are infected. Obad et al 
demonstrated using short LNA antagomiRs to target entire miRNA families [81], and this 
strategy could be used to inhibit miRNAs that are overexpressed during infection and 
increase either virus infection or contribute to pathogenesis. We show here that miRs-
29a, -29b, -9 and -146a are four anti-SIV miRNAs that have the potential to be used as 




To our knowledge, this study is the first report linking viral as wel as innate immune 
modulation of miRNAs with direct targeting of viral RNAs and inhibition of virus 
production. The significant role of miRNAs in the pathogenesis of HIV is underscored by 
the abundance of reports demonstrating miRNA efects on disease progression as wel as 
effects of virus on miRNA expression. The early induction of miRs-29a, -29b, -9 and -
146a caused by SIV and the significant inhibition of virus production very early in 
infection suggests potential for using these as wel as other miRNAs for treatment of HIV 
in addition to other infectious diseases. Our macaque model of SIV provides an ideal 
model for testing delivery and efficacy of treatment with miRNAs. Future strategies 
include using anti-SIV miRNAs or miRNAs that target transcription factors and other 
proteins necessary for replication of HIV and SIV. Targeted delivery to infected cels or 
individual cel types may reduce negative of-target effects suffered by many patients 





Animal studies were approved by the Johns Hopkins University Institutional Animal 
Care and Use Commitee (Protocol # PR09M296) and conducted in accordance with the 
Weatheral Report, the Guide for the Care and Use of Laboratory Animals, and the 
USDA Animal Welfare Act. 
 
miRNA Prediction Programs 
The SIV 3’ UTR sequence, consisting of nef/U3-R (SIV/17E-Fr nucleotides 9462-10155), 
was analyzed for miRNA binding sites. Results from miRanda [59] and RNAhybrid [60] 
were compiled to identify predicted miRNA binding sites within the SIV 3’ UTR. The 
minimum free energy cutoff for miRNA consideration was set at -20 kcal/mol, and the 
free energy of each miRNA/target site interaction is in supplemental Table 1. 
 
Luciferase Assays 
The SIV 3’ UTR (nef/U3-R, SIV 17E-Fr nts 9458-10160) was cloned into the 
psiCHECK-2 vector (Promega) 3’ of a Renila luciferase reporter gene. 293T cels were 
plated at 80,000 per wel of a 24-wel plate. Cels were approximately 90% confluent 24 
hours later for co-transfection of individual miRNA mimics and either psiCHECK-2 
plasmid plus SIV insert or psiCHECK-2 plasmid with no insert. Controls were 
transfected with either psiCHECK-2 or psi-CHECK-SIV 3’ UTR, but no miRNA mimics. 
Cels were harvested 24 hours later and assayed for luciferase expression using the 
Renila Luciferase Assay System (Promega) and measured on (Fluoroskan Ascent FL, 
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Thermo Scientific). The raw luciferase value of each sample was normalized to total 
protein for that sample to control for wel-to-wel differences in cel number. Firefly 
luciferase was not used for normalization as al four miRNAs reduced levels of this 
control reporter. Several individual plasmids were co-transfected to use as transfection 
controls but were not able to be included because expression of al was modulated by 
some or al of miRs-29a, -29b, -9 and -146a. Experiments were repeated replacing the 
miRNA mimics with scrambled mimics (scrambled #1 Ambion mirVana miRNA mimic 
Negative Control #1, scrambled #2 Sigma Mission miRNA Negative Control 2). 
 
Macrophages 
Isolation and culture  
Macaque macrophages were obtained from rhesus and pigtail macaque donors. Human 
macrophages were obtained from leukopacks from anonymous donors of the Johns 
Hopkins Hospital HATS donation center. Whole blood was diluted with HBSS, loaded 
onto a Ficol gradient and centrifuged for 30 minutes at 2000 rpm. Plasma was removed 
and PBMCs were removed from the interface of plasma and Ficol. Cels were washed in 
HBSS and peleted (1500 rpm for 10 minutes) twice prior to red blood cel lysis (15 ml of 
155 mM NH4Cl, 10 mM KHCO3 and 1 mM EDTA for 15 minutes at 37
oC). 35 ml of 
HBSS was added, and PBMCs were centrifuged to remove red blood cel lysis buffer. 
Cels from individual donors were plated separately (donor samples were not pooled) at 
4x106 cels per wel in 12-wel plates or 10x106 cels per wel in 6-wel plates and 
cultured for 7 days in medium containing M-CSF and 20% autologous serum. One half of 
the total volume of medium was replaced on day 3. On day 7, cels were washed 3 times 
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with PBS to remove non-adherent cels. The medium was replaced the same as above, 
only with 10% serum. Infection and treatments were al performed on day 8 after plating.  
 
miRNA Transfection and SIV Infection 
Rhesus or pigtail macaque macrophages were approximately 90% confluent on day eight 
post-plating when transfected with 100 nM of individual miRNAs or miRNA antagonists 
(Qiagen) for 6 hours using Lipofectamine 2000 (Invitrogen/Life Technologies) diluted in 
OptiMEM Reduced Serum Medium (Life Technologies) as per manufacturer’s 
instructions. Mock transfections included Lipofectamine 2000 and OptiMEM, but no 
miRNA mimic. Twenty-four hours later, cels were infected with macrophage tropic SIV 
17E-Fr [GenBank:AY033146.1] at an MOI of 0.05 for six hours. Folowing infection, 
cels were washed 3 times with PBS, and fresh medium was added. Supernatants and 
cels were colected at 24, 48 and 72 hours post infection to measure virus production and 
viral RNA levels, respectively. Al results shown are the average of at least three separate 
experiments.  
 
IFNβ and TNFα Treatment 
Day 8 pigtail macaque macrophages were approximately 90% confluent when treated 
with either 100 U/ml IFNβ (PBL Interferon Source) or 20 ng/ml TNFα (R&D Systems, 
human 210-TA-010, macaque 1070-RM-025). Total RNA was isolated from control and 
treated samples at 2, 4, 8, 12 and 24 hours post-infection. Al results shown are the 




Al RNA isolation was performed using the mirVana miRNA Isolation Kit (Ambion). 
Cels were harvested in 600 µl Lysis/Binding Buffer and eluted with 100 µl water. 
Samples were treated with 2 µl TURBO DNase (Ambion) for 45 minutes at 37oC. 
Samples were re-extracted using the mirVana miRNA Isolation Kit cleanup protocol and 
eluted with 100 µl water. 
 
Analysis of SIV p27  
200 µl of supernatant was used for p27 assays (Zeptometrix). The assay was performed 
folowing an overnight incubation of samples in lysis buffer at 37oC. p27 levels were 
determined based on the manufacturer’s provided standard. Al results shown are the 
average of at least three separate experiments.  
 
RT-qPCR 
Results are reported as fold change using the ΔΔCq method. Al statistics reported 
represent 2-tailed t tests assuming unequal variance, performed on ΔΔCq values of time-
point matched samples with untreated/uninfected controls. Al results shown are the 
average of at least three separate experiments.  
 
SIV Transcripts 
250 ng of RNA was used for reverse transcription cDNA synthesis (Superscript III, 
Invitrogen/Life Technologies). RT-qPCR was performed as described previously using 
primers and probes specific for SIV gag and tat/rev transcripts [82]. Quantification cycle 
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(Cq) values were normalized to an average of the GAPDH and18S Cq values as wel as 
to time-point controls.  
 
Taqman RT-qPCR – mature miRNAs 
10 ng of total RNA was used for reverse transcription cDNA synthesis using the Taqman 
microRNA Reverse Transcription Kit (Applied Biosystems) and Taqman assays for 
individual miRNAs. 5 µl of cDNA was used for RT-qPCR with individual miRNA 
Taqman assays. Cq values were normalized to a U6 internal control as wel as to time-
point controls.  
 
Taqman RT-qPCR – pri-miRNAs 
100-250 ng of total RNA was used for reverse transcription cDNA synthesis using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 4 µl of cDNA 
was used for RT-qPCR with Taqman precursor miRNA assays for individual pri-




HeLa cels were plated using 200,000 cels per well of a 6-wel plate and 24 hours later 
were approximately 90% confluent when transfected with Lipofectamine 2000 
(Invitrogen) with 400 pmol of a biotinylated 50-nucleotide WT or mutant RNA oligo 
corresponding to the predicted regions of binding for individual miRNAs (see Figure 
5A). Twenty-four hours after transfection cels were fixed in 0.5% formaldehyde for 15 
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minutes at room temperature. Cross-linking was stopped by 5 minute incubation at room 
temperature in 0.25 M glycine, pH 7. Fixed cels were lysed in modified RIPA buffer 
[82] for 30 minutes at 4oC. Lysed cels were centrifuged for 10 minutes at 14,000 rpm at 
4oC. 5% of total sample volume was taken for input. Lysates were incubated for 30 
minutes at room temperature with 100 µl of streptavidin beads (Dynabeads MyOne 
Streptavidin C1, Life Technologies) to pul down endogenous miRNAs bound to the 
biotinylated oligos. Beads were washed 3 times with 500 µl RIPA Buffer. After reverse 
cross-linking (5 minutes at 65oC in 100µl of 95% formamide, 10 mM EDTA pH 8.0), 
500 µl of mirVana Binding/Lysis Buffer was added to the supernatant and RNA was 
extracted using the mirVana miRNA Isolation Kit (Ambion). 10 µl of total RNA was 
used in Taqman miRNA-specific qPCR primer/probe assays to detect specific miRNAs 
bound to individual oligos containing predicted miRNA binding sites. Percent of pul 





For mRNA and miRNA comparisons that only consisted of two groups 
(uninfected/untreated versus infected/treated) a paired, two-sided t test was performed on 
the wel-specific observations (relative to the control average) at each time point. Each 
miRNA was statisticaly evaluated as the duplicate- or triplicate-averaged difference from 
C(q) U6 or 18S and GAPDH relative to control. Statistical significance, p-value <0.05, 
indicates an effect of intervention. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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Figure 1. Predicted miRNA binding sites within the 3’ UTR of SIV. miRanda and 
RNAhybrid prediction programs identified miRNA response elements (MREs) for miRs- 
29a, -29b, -9 and -146a. A) A graphic representation of the SIV 3’ UTR with predicted 







Figure 2. Four miRNAs reduce levels of SIV virus production. Primary macaque 
macrophages were transfected with 100 nM miRNA mimics, then infected with SIV 
(MOI 0.05) 24 hours after transfection. Supernatants were colected at 24, 48 and 72 
hours post-infection and analyzed for virus production. Data shown is an average of at 
least 3 experiments for each miRNA at each time point. (x) indicates levels at or below 
the limit of detection, ~60 pg/ml (gray line). Results reported are p27 pg/ml values 
averaged from at least 3 separate experiments. Al statistics reported are the result of a 
paired, two-sided t test performed on p27 values of time-point matched samples with 








Figure 3. Four miRNAs reduce levels of ful length and multiply spliced viral RNAs. 
Primary macaque macrophages were transfected with 100nM of either miRNA mimics or 
antagonists, then infected with SIV (MOI 0.05) 24 hours after transfection. Cel lysates 
were colected at 24, 48 and 72 hours post-infection for miRNA experiments and 48 
hours for miRNA antagonist experiments. Levels of ful length (A, C) and spliced (B) 
RNA was measured by RT-qPCR. Values are expressed as fold change over SIV-only 




Figure 4. miRs-29a, -29b, -9 and -146a reduce expression of a luciferase reporter 
and target predicted binding sites in the 3’ UTR of SIV. A) SIV nef/U3-R region was 
cloned into the psiCHECK-2 plasmid (Promega). 293T cels were co-transfection with 50 
nM or 100 nM of each individual miRNA mimic or scrambled mimic and 100 ng of 
either psiCHECK-2 + SIV insert or psiCHECK-2 alone. Control samples were 
transfected with either psiCHECK-2 or psi-CHECK-SIV 3’ UTR, and no miRNA 
mimics. Cels were harvested 24 hours after transfection. Data shown is an average of 
four separate experiments and represents miRNA effect on luciferase expression for 
psiCHECK-SIV 3’ UTR over psiCHECK only. B) WT and mutant biotin-labeled oligos 
corresponding to SIV RNA sequences containing predicted miRNA binding sites. WT 
oligo is show on top and mutant on the botom. Boxed bases on the WT oligo denote 
miRNA seed binding site in SIV sequence. Mutant oligo highlighted bases denote the 
change in the seed-binding region. Annotation is based on SIV sequence AY033146. C) 
100 pmol of individual WT or mt oligos were transfected into HeLa cells and lysates 
colected 24 hours after transfection. Oligos were puled down using Streptavidin beads 
and assayed for binding to endogenous celular miRNAs using Taqman RT-qPCR. 
Percent of input was calculated for each sample (see methods) and data is presented as 
(% of input mt )/(% of input WT) with % of input of WT set to 100%. In each 
experiment, the value of the oligo which puled down the highest percentage of the 
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individual endogenous miRNA was set to 100% and binding by other oligos was 
compared to this value. Data shown is an average of 4 experiments. Statistics represent 
the comparison of percent of miRNA bound to the WT oligo compared to percent of 
miRNA puled down by the coresponding mt oligo and are reported as a two-tailed t test 
assuming unequal variance. 
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Figure 5. SIV infection increases levels of mature miR- 29a (A), -29b (B), -9 (C) and 
-146a (D) . Macaque macrophages were infected with SIV (MOI 0.05). Cels were 
harvested at 2, 4, 8, 12, 24 and 48 hours after infection and RNA was isolated. Taqman 
miRNA RT-qPCR assays were used to measure levels of mature miRNAs. Results were 
normalized to U6, then to uninfected samples for the individual time points (ΔΔCq 
method). Values are expressed as fold induction of miRNAs over uninfected controls 




Figure 6. IFNβ increases levels of mature miRNAs and primary miRNA transcripts 
in human macrophages. Human macrophages were treated with 100 U/ml IFNβ and 
cels were harvested at 4, 8, 12 and 24 hours after treatment and RNA isolated. A-D) 
Taqman miRNA RT-qPCR assays were used to measure levels of mature miRNAs. E-H) 
Taqman pri-miRNA RT-qPCR assays were used to measure levels of primary miRNA 
transcripts. Results were normalized to U6. Values are expressed as fold induction of 
miRNAs over uninfected controls using the ΔΔCq method and data shown is an average 





Figure 7. TNFα increases levels of mature miRNAs and primary miRNA transcripts 
in human macrophages. Human macrophages were treated with 20 ng/ml TNFα. Cels 
were harvested at 2, 4, 8, 12 and 24 hours after treatment and RNA isolated. A-D) 
Taqman miRNA RT-qPCR assays were used to measure levels of mature miRNAs. E-H) 
Taqman pri-miRNA RT-qPCR assays were used to measure levels of primary miRNA 
transcripts. Results were normalized to U6. Values are expressed as fold induction of 
miRNAs over uninfected controls using the ΔΔCq method and data shown is an average 
of at least 3 experiments.  
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Figure S1 A-D. IFNβ increases levels of mature miRNAs in macaque macrophages. 
Macaque macrophages were treated with 100U/ml IFNβ. Cels were harvested at 4, 8, 12 
and 24 hours after treatment and RNA was isolated. Taqman miRNA RT-qPCR assays 
were used to measure levels of mature miRNAs. Results were normalized to U6. Values 
are expressed as fold induction of miRNAs over untreated controls using the ΔΔCq 
method and data shown is an average of at least 3 experiments. 
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Figure S2. SIV infection and IFNβ stimulation increases mxa levels. IFNβ decreases 
SIV RNA levels. Macaque macrophages were infected with SIV (A), infected with SIV 
and treated with IFNβ (C) and primary human macrophages were treated with IFNβ (B). 
RT-qPCR using sequence-specific primers and probe for mxa was used to measure mxa 
and SIV RNA levels. Results were normalized to 18S. Values are expressed as fold 
induction of mxa over uninfected/untreated controls using the ΔΔCq method and data 











Figure S3. TNFα induced expression of mxa in primary macaque and human 
macrophages. Macaque (A) and human (B) macrophages were treated with 20 ng/ml 
macaque or human TNFα. RNA was isolated at 2, 4, 8, 12 and 24 hours after treatment. 
Sequence-specific primers and probe for mxa were used for RT-qPCR. Results were 
normalized to 18S. Values are expressed as fold induction of mxa over untreated controls 
using the ΔΔCq method and data shown is an average of at least 3 experiments. 
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Figure S4A-D. TNFα increased levels of mature miRNAs in macaque macrophages. 
Macaque macrophages were treated with 20 ng/ml TNFα. Cels were harvested at 4, 8, 
12 and 24 hours after treatment and RNA isolated. Taqman miRNA RT-qPCR assays 
were used to measure levels of mature miRNAs. Results were normalized to U6. Values 
are expressed as fold induction of miRNAs over untreated controls using the ΔΔCq 










Table S1. Binding energies for each miRNA site within the SIV LTR sequence, 
predicted by miRanda and RNAhybrid. The minimum binding energy threshold was set 



















V. SUMMARY AND FUTURE DIRECTIONS 
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The work included in this dissertation demonstrates how miRNAs, discovered only a 
short time ago, have the ability to target and regulate the expression of not only 
endogenous host genes, but also that of non-evolutionary targets, such as viruses. We 
show here that miRNA expression can differ dramatically between cells that have the 
ability to become productively infected with HIV/SIV and those that do not. Our work 
also identified functional miRNA binding sites within the SIV genome, and addition of 
these miRNAs to SIV-infected cells leads to a decrease in virus production. We found 
miRNA regulation of IFNβ, a major type I IFN, and regulation by IFNβ and TNFα, for 
some of these same miRNAs. This work underscores the multifaceted and complex 
nature of the immune system and the importance of understanding the fine-tuning 
mechanisms underlying its action. 
 
Results here show miRNA regulation of SIV infection. Further study could be done to 
determine if this effect is in fact due to direct miRNA targeting of SIV mRNAs or of 
another factor necessary for virus replication. Mutations predicted to disrupt miRNA 
targeting of seed binding regions could be made to the SIV genome. If SIV RNAs contain 
true functional miRNA binding sites, then individual miRNAs should have no impact on 
replication of the virus containing the mutation for that miRNA’s specific seed-binding 
site. These studies may be complicated because the binding sites for all four miRNAs lie 
near or within the trans-activation response (TAR) element. Because this stretch of viral 
sequence is essential for productive infection, it may be difficult to introduce mutations 
that impact miRNA binding without negatively impacting virus replication. 
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It would also be interesting to investigate whether miRNA inhibition of SIV replication is 
more beneficial to the host or to the virus. Infected CD4+ T cels, and potentialy 
macrophages, can each serve as a latent reservoir for HIV and SIV. Latency alows viral 
DNA to persist in host cels with the ability to have a rebound in virus replication upon 
activation of the resting/latent cel. The miRNA action we observed may contribute to a 
latent state, thereby ensuring survival of the viral genome. Searching for viral escape 
mutants by deep sequencing of the viral genome, after miRNA treatment of infected 
cels, would be one way to analyze this. The presence of virus escape mutants would 
suggest that the miRNA action is detrimental to the virus life cycle.  
 
The impact of miRNAs on viral pathogenesis is a new area of research. The virus-host 
relationship is an elaborate web of interactions and miRNAs are proving to be key 
players. The immune response requires a delicate balance of eliminating infection while 
limiting damage due to inflammation and cel death. Understanding the nuance of the 
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